cyclosporine has been researched along with Dermatitis, Atopic in 311 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 53 (17.04) | 18.2507 |
| 2000's | 69 (22.19) | 29.6817 |
| 2010's | 131 (42.12) | 24.3611 |
| 2020's | 58 (18.65) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, SH; Lee, SH; Yu, J | 1 |
| Bjerregård Øland, C; Gutermuth, J; Pink, AE; Soldbro, L; Weidinger, S; Worm, M | 1 |
| Balogh, EA; Feldman, SR; Sahni, VN; Strowd, LC | 1 |
| Ardeleanu, M; Daoud, M; de Bruin-Weller, M; Ferrucci, SM; Jayawardena, S; Patrizi, A; Pink, AE; Schuttelaar, MLA; Svensson, A; Tauber, M | 1 |
| Augustin, M; Bieber, T; Brinker, D; DeLozier, AM; Dutronc, Y; Eyerich, K; Ghislain, PD; Janes, JM; Lacour, JP; Liao, R; Meskimen, E; Paul, C; Reich, K; Tsunemi, Y; Yang, FE | 1 |
| Feldman, SR; Shah, MA; Singh, R; Strowd, LC; Taylor, A | 1 |
| Napolitano, M; Patruno, C; Potestio, L | 1 |
| Agner, T; Alfonso, JH; de Graaf, M; De Schepper, S; Deleuran, M; Despontin, K; Elenius, V; Ghislain, PD; Huilaja, L; Janmohamed, SR; Johansson, EK; Kvenshagen, BK; Mandelin, JM; Olset, H; Schuttelaar, MLA; Svensson, A; Thyssen, JP; van Tuyll van Serooskerken, AM; Vestergaard, C | 1 |
| Choi, A; Jeon, JY; Lee, JH; Noh, Y; Oh, IS; Shin, JY; Son, SW; Yoo, HJ | 1 |
| Arents, B; Aszodi, N; Avila Valle, G; Barbarot, S; Bieber, T; Brough, HA; Calzavara Pinton, P; Christen-Zäch, S; Deleuran, M; Dittmann, M; Dressler, C; Fink-Wagner, AH; Flohr, C; Fosse, N; Gáspár, K; Gerbens, L; Gieler, U; Girolomoni, G; Gregoriou, S; Kinberger, M; Mortz, CG; Nast, A; Nygaard, U; Redding, M; Rehbinder, EM; Ring, J; Rossi, M; Serra-Baldrich, E; Simon, D; Szalai, ZZ; Szepietowski, JC; Torrelo, A; Werfel, T; Wollenberg, A | 1 |
| Artime, E; Díaz-Cerezo, S; Hernández-Subirá, I; Huete, T; Lledo-Bryant, L; Mert, C; Serra, E; Sicras-Mainar, A | 2 |
| Munawar, L; Norden, A; Oulee, A; Thyssen, J; Wu, J | 1 |
| Cheirif-Wolosky, O; Elizalde-Jiménez, IG; Romero, MTG | 1 |
| Wallace, DV | 1 |
| Deshpande, GA; Fukui, S; Kaname, S; Kishimoto, M; Komagata, Y; Ohyama, M | 1 |
| Bizikova, P; Herrmann, I; Holmes, J; Mamo, LB; Mohammed, JP; Murphy, KM | 1 |
| Beckmann, KM; Hetzel, U; Martini, F; Rostaher, A | 1 |
| Adam, DN; Beecker, JR; Gooderham, MJ; Hong, CH; Jack, CS; Jain, V; Lansang, P; Lynde, CW; Papp, KA; Prajapati, VH; Turchin, I; Yeung, J | 1 |
| Austel, M; Banovic, F; Vargo, C | 1 |
| Ahmed, F; Takeshita, J; Wan, J | 1 |
| Kim, BS; Trier, AM | 1 |
| Arias Santiago, S; Ballano Ruiz, A; Batalla, A; Bertolín-Colilla, M; Betlloch, I; Botella Estrada, R; Carrascosa, JM; Carretero Hernández, G; Chicharro, P; Curto Barredo, L; de la Cueva Dobao, P; Del Alcázar, E; Descalzo, MA; Elosua-González, M; Flórez Menéndez, Á; García-Doval, I; Gilaberte Calzada, Y; Gimenez Arnau, AM; Gonzalez Quesada, A; Jin Suh Oh, H; Mauleón Fernández, C; Montero-Vilchez, T; Munera-Campos, M; Navarro Bielsa, A; Rodríguez Serna, M; Rosell Díaz, A; Roustan Gullón, G; Sánchez-Pérez, J; Santamaría, C; Silvestre, JF | 1 |
| Bangert, C; Burnett, P; Fölster-Holst, R; Jones, J; Lacour, JP; Loesche, C; Novak, N; Skvara, H; Stingl, G | 1 |
| Abraham, S; Augustin, M; Ertner, K; Handrick, C; Harder, I; Hartmann, J; Häsler, R; Haufe, E; Heratizadeh, A; Kleinheinz, A; Lieb, W; Moitinho-Silva, L; Quist, S; Rodriguez, E; Sander, N; Schäkel, K; Schenck, F; Schmitt, J; Schwarz, B; Staubach-Renz, P; Sticherling, M; Tittmann, L; Weidinger, S; Weisshaar, E; Werfel, T; Wiemers, F; Wildberger, J; Wollenberg, A | 1 |
| Dunn, CL; Dunn, CP; Petroni, DH | 1 |
| Arias, P; Borobia, AM; Carcas, AJ; Díaz-García, L; Feltes Ochoa, R; García-García, I; Hernández Cano, N; Herranz Pinto, P; Jiménez González, M; López-Granados, E; Marín-Candón, A; Martínez-Feito, A; Mayor-Ibarguren, A; Rosas-Alonso, R; Seco-Meseguer, E | 1 |
| Choudhary, A; Gehlawat, T; Jangid, N; Mistry, D; Parmar, KS; Shah, BJ; Shah, SR; Vyas, HR | 1 |
| Ashoor, F; August, S; Baron, S; Beattie, P; Brown, SJ; Browne, F; Cork, MJ; Esdaile, B; Flohr, C; Gach, JE; Greenblatt, D; Hearn, R; Hilger, E; Howard, E; Irvine, AD; Jones, AP; Lovgren, ML; McPherson, T; O'Kane, D; Ravenscroft, J; Rosala-Hallas, A; Sach, TH; Shaw, L; Sinha, MD; Spowart, C; Taams, LS; Thomas, BR; Wan, M; Williamson, PR | 1 |
| Ballona, R; Bravo-Puccio, F; Butron, P; Castro-Vargas, EG; Galvan, C; Gereda-Solari, JE; Larco-Sousa, JI; Matos, E; Torres-Ibérico, R | 1 |
| Astrid, B; Azib, S; Chuffard, M; Dezoteux, F; Drumez, E; Staumont-Sallé, D | 1 |
| Blake, SC; Murrell, DF | 1 |
| Badihi, A; Benhamron, S; Benita, S; Frušić-Zlotkin, M; Nassar, T; Soroka, Y; Tzur, T | 1 |
| Dahabreh, D; Dubin, C; Garcet, S; Glickman, JW; Guttman-Yassky, E; Han, J; Krueger, JG; Pavel, AB | 1 |
| Baker, C; Charlton, O; Foley, P; Phan, K; Smith, SD | 1 |
| Abasq, C; Barbarot, S; Bekel, L; Bessis, D; Bonniaud, B; Bouzille, G; Chambrelan, E; Delaunay, J; Droitcourt, C; Du Thanh, A; Dupuy, A; Kupfer, I; Mahé, E; Mallet, S; Maruani, A; Miquel, J; Phan, A; Poizeau, F; Puzenat, E; Raison-Peyron, N | 1 |
| Deleuran, M; Flohr, C; Gerbens, LAA; Irvine, AD; Logan, K; Ouwerkerk, W; Schmitt, J; Spuls, PI; Vermeulen, FM; Vestergaard, C | 1 |
| Silverberg, JI; Singh, P | 1 |
| Feldman, SR; Ghamrawi, RI; Howell, AN; Strowd, LC | 1 |
| Ariëns, LFM; Bakker, DS; de Bruin-Weller, MS; de Graaf, M; de Ridder, I; Haeck, I; Kamsteeg, M; Oosting, AJ; Romeijn, GLE; Schuttelaar, MLA; Sloeserwij, A; Spekhorst, LS; Thijs, JL; van der Schaft, J | 1 |
| Arents, BWM; Bohdanowicz, M; Burton, T; Di Giorgio, S; Drucker, AM; Ellis, AG; Flohr, C; Küster, D; Mashayekhi, S; Rochwerg, B; Schmitt, J; Siegels, D; Spuls, PI; Yiu, ZZN | 1 |
| Amimoto, Y; Ideguchi, H; Murakami, Y; Nishie, H; Odajima, H; Sugiyama, A | 1 |
| Garland, T; Grindlay, DJC; Harman, KE; Olabi, B; Rogers, NK; Worboys, S | 1 |
| Dal Bello, G; Girolomoni, G; Gisondi, P; Maurelli, M; Schena, D | 1 |
| Jaworek, A; Jaworek, M; Matusiak, Ł; Szafraniec, K; Szepietowski, JC; Wojas-Pelc, A | 1 |
| Abraham, S; Binnmyr, J; Brockow, K; Flohr, C; Halken, S; Heratizadeh, A; Irvine, AD; Mortz, CG; Muraro, A; Schmid-Grendelmeier, P; Schmitt, J; Siegels, D; Van der Poel, LA; Weidinger, S; Werfel, T | 1 |
| High, EJ; Olivry, T | 1 |
| Miyano, K; Tsunemi, Y | 1 |
| Abraham, S; Boraczynski, N; Gerdes, S; Handrick, C; Harder, I; Haufe, E; Heratizadeh, A; Kleinheinz, A; Litman, T; Möbus, L; Rodriguez, E; Schmitt, J; Schwarz, A; Stölzl, D; Wehkamp, U; Weidinger, S; Werfel, T | 1 |
| Agner, T; Ardeleanu, M; Arenberger, P; Bruin-Weller, M; Eckert, L; Ferrucci, SM; Gimenez-Arnau, AM; Jayawardena, S; Nosbaum, A; Ozturk, ZE; Patrizi, A; Pink, AE; Rizova, E; Roquet-Gravy, PP; Schuttelaar, MLA; Svensson, A | 1 |
| Bizikova, P; Mueller, RS; Nuttall, T; Prost, C; Schulz, B | 1 |
| Caldarola, G; Chiricozzi, A; D'Urso, DF; De Simone, C; Gori, N; Malvaso, D; Peris, K | 1 |
| Ardern-Jones, MR; Barbara, R; Corden, E; Hossain, PN; Martinez-Falero, BS; O'Driscoll, D; Popiela, MZ; Turnbull, AMJ | 1 |
| Bennett, M; Bourke, J; Bowe, S; Kiely, L; Murphy, M; O'Connor, C | 1 |
| Bayerl, C; Herr, R; Kromer, C; Pino Lopez, J; Schaarschmidt, ML; Schmieder, A | 1 |
| Colonna, C; Gelmetti, C; Monzani, NA; Ponziani, A; Zussino, M | 1 |
| Augustin, M; Cabral, C; Ihle, P; Kienitz, C; Pittrow, D; Theobald, K; Zietze, HA | 1 |
| De Simone, C; Garcovich, M; Garcovich, S; Gnarra, M | 1 |
| Honda, T; Kabashima, K; Kitayama, N; Nakashima, C; Nonomura, Y; Otsuka, A | 1 |
| Amano, W; Hayashi, M; Kakimoto, K; Katsuda, Y; Kimoto, Y; Konishi, N; Shinozaki, Y; Taniai-Riya, E; Tanimoto, A; Toyoda, K; Yamamoto, Y | 1 |
| Aubert, H; Barbarot, S; Bernier, C; Daguzé, J; Gaultier, A; Nguyen, JM; Stalder, JF | 1 |
| Beck, LA; Prezzano, JC | 1 |
| Durán-McKinster, C; Silverberg, NB | 1 |
| Elmariah, SB | 1 |
| Haarstad, AC; Heinrich, NA; McFadden, RA; Tomlinson, DJ | 1 |
| Borok, J; Davis, DM; Lio, P; Spergel, J; Udkoff, J | 1 |
| Borowski, S; Escalada, M; Mahabir, SP; Moyaert, H; Stegemann, MR; Van Brussel, L; Walters, RR | 1 |
| Diaz, S; Gilbert, S; Koch, SN; Rendahl, A; Torres, SMF | 1 |
| Akinlade, B; Chen, Z; Cork, MJ; de Bruin-Weller, M; Eckert, L; Gadkari, A; Graham, NMH; Hultsch, T; Pirozzi, G; Radin, A; Reich, K; Shumel, B; Smith, CH; Thaçi, D; Zhang, Q | 1 |
| Álvarez Martín, T; Ferrando Piqueres, R; Pitarch Bort, G; Raga Jiménez, C | 1 |
| Thyssen, JP | 1 |
| de Bruin-Weller, M; Graham, NMH; Pirozzi, G; Shumel, B | 1 |
| Lacour, JP | 1 |
| Beneton, N; Bouzillé, G; Droitcourt, C; Dupuy, A; Law Ping Man, S; Safa, G | 1 |
| Heratizadeh, A; Pumnea, T; Werfel, T; Wollenberg, A | 1 |
| Ahrens, K; Marsella, R; Santoro, D; White, AG | 1 |
| Bruijnzeel-Koomen, CAFM; de Bruin-Weller, MS; Garritsen, FM; Maitland-van der Zee, AH; van den Broek, MPH; van den Heuvel, JM | 1 |
| Cho, YS; Chung, BY; Kim, HO; Park, CW; Park, SY; Son, JH | 1 |
| Ashoor, F; Baron, S; Beattie, P; Browne, F; Flohr, C; Irvine, AD; Jones, AP; O'Neill, L; Rosala-Hallas, A; Sach, T; Spowart, C; Taams, L; Walker, C; Wan, M; Webb, N; Williamson, P | 1 |
| Schmitt, J | 2 |
| Giavina-Bianchi, M; Giavina-Bianchi, P | 1 |
| Gortel, K | 1 |
| Bercovitch, L; Drucker, AM | 1 |
| Jwo, K; Mosaed, S; Shen, E; Smith, J; Xie, K | 1 |
| Bruijnzeel-Koomen, CAFM; de Bruin-Weller, MS; Drylewicz, J; Giovannone, B; Hijnen, D; Knol, EF; Nierkens, S; Thijs, JL | 1 |
| Aydoğan, K; Bülbül Başkan, E; Sarıcaoğlu, H; Yazici, S; Zorlu, Ö | 1 |
| Grindlay, DJC; Harman, KE; Lloyd-Lavery, A; Rogers, NK; Solman, L; Thomas, KS | 1 |
| Alexander, H; Flohr, C; Jabbar-Lopez, ZK; Manca, A; Patton, T | 1 |
| Abad, ED; Cavalcante, FS; da Silva, AMP; Dos Santos, KRN; Ferreira, DC; Goudouris, E; Hofer, C; Prado, EA; Ribeiro, M; Rosado, AS; Saintive, S; van Elsas, JD | 1 |
| Ariëns, LFM; Ayyagari, R; Bégo-Le Bagousse, G; Chen, Z; De Bruin-Weller, M; Eckert, L; Gadkari, A; Graham, NMH; Kuznik, A; Lu, Y; Pirozzi, G; Rizova, E; Terasawa, E; van Os-Medendorp, H | 1 |
| Navarro-Mira, MÁ; Rahhal-Ortuño, M; Roca-Ginés, J; Rodríguez-Serna, M; Torres-Navarro, I | 1 |
| Arima, K; Dorey, J; Fujita, H; Fukushima, A; Igarashi, A; Inoue, T; Taguchi, Y | 1 |
| Brazís, P; Dalmau, A; Fuertes, E; Olivar, A; Ordeix, L; Pérez, C; Puigdemont, A; Ravera, I | 1 |
| Burrows, AK; Siak, MK | 1 |
| Flohr, C; Irvine, AD | 1 |
| Bensignor, E; Carmichael, J; Dip, R; Letellier, I; Roberts, E; Rosenkrantz, W; Strehlau, G | 1 |
| Arkin, L; Bayers, SL; Bohaty, B; Paller, AS | 1 |
| Omoto, M; Satake, Y; Shimazaki, J; Shimazaki-Den, S; Shimmura, S; Shimmura-Tomita, M; Tsubota, K | 1 |
| Irvine, AD; McMenamin, M; O'Mahony, D; Wall, D | 1 |
| Kuester, D; Limpens, J; Roekevisch, E; Schmitt, J; Spuls, PI | 1 |
| Flohr, C; Tsakok, T | 1 |
| Irvine, AD | 1 |
| DeBoer, DJ | 1 |
| Nuttall, T; Reece, D; Roberts, E | 1 |
| Forsythe, P; Paterson, S | 1 |
| Cardinale, I; Czarnowicki, T; de Guzman Strong, C; Dhingra, N; Finney, R; Gilleaudeau, P; Gonzalez, J; Guttman-Yassky, E; Khattri, S; Krueger, JG; Rozenblit, M; Shemer, A; Suárez-Fariñas, M; Sullivan-Whalen, M; Xu, H; Zheng, X | 1 |
| Begolka, WS; Berger, TG; Bergman, JN; Block, J; Chamlin, SL; Cohen, DE; Cooper, KD; Cordoro, KM; Davis, DM; Eichenfield, LF; Elmets, CA; Feldman, SR; Hanifin, JM; Harrod, CG; Krol, A; Margolis, DJ; Paller, AS; Schwarzenberger, K; Sidbury, R; Silverman, RA; Simpson, EL; Tom, WL; Williams, HC | 1 |
| Cardinale, I; Gilleaudeau, P; Guttman-Yassky, E; Khattri, S; Krueger, JG; Rozenblit, M; Shemer, A; Suarez-Farinas, M; Sullivan-Whalen, M; Xu, H; Zheng, X | 1 |
| Altomare, G; Ayala, F; Bardazzi, F; Bellia, G; Chimenti, S; Colombo, D; Flori, ML; Girolomoni, G; Micali, G; Parodi, A; Peris, K; Vena, GA | 2 |
| Ohtsuka, T | 1 |
| Cosgrove, SB; Davis, KR; King, VL; Little, PR; Stegemann, MR | 1 |
| Gaffin, JM; Kanchongkittiphon, W; Phipatanakul, W | 1 |
| Bruijnzeel-Koomen, CAFM; Christoffers, WA; de Bruin-Weller, MS; de Jong, EMGJ; Kievit, W; Politiek, K; Schuttelaar, MLA; van den Reek, JMPA; van der Schaft, J | 1 |
| Duse, M; Nebbioso, M; Occasi, F; Petrarca, L; Salvatori, G; Zicari, AM | 1 |
| de Bruin-Weller, MS; Deinum, J; Garritsen, FM; Roekevisch, E; Spuls, PI; van der Schaft, J | 1 |
| Bruijnzeel-Koomen, CA; de Bruin-Weller, MS; Deinum, J; van der Schaft, J; van Zuilen, AD | 1 |
| Iwata, K; Kaneko, M; Marumoto, A; Tanioka, H | 1 |
| Silverberg, JI | 1 |
| Goodnight, AL | 1 |
| Adamek, Ł; Pomorski, Z; Szczepanik, M; Wilkołek, P; Zając, M | 1 |
| Cassano, N; Garcovich, C; Garcovich, S; Vena, GA | 1 |
| Kraft, D; Linhart, B; Lucae, S; Schmid-Grendelmeier, P; Valenta, R; Wüthrich, B | 1 |
| King, S; Roberts, ES; Roycroft, L; Tapp, T; Trimmer, A | 1 |
| Luger, TA; Tsianakas, A | 1 |
| Berg, MT; Bruijnzeel-Koomen, CA; de Bruin-Weller, MS; Hijnen, DJ; van den Broek, MP; van der Schaft, J; van Schaik, RH; van Zuilen, AD | 1 |
| Notaro, ER; Sidbury, R | 1 |
| Beccati, M; Comazzi, S; Cornegliani, L; Fanton, N; Martini, V | 1 |
| Kamata, Y; Kina, K; Ko, KC; Matsuda, H; Ogawa, H; Ogawa, M; Takahashi, N; Takamori, K; Tominaga, M; Umehara, Y | 1 |
| Amazan, E; Boralevi, F; Ezzedine, K; Milpied, B; Seneschal, J; Taïeb, A; Védie, AL | 1 |
| Friberg, C; Griffin, C; King, S; Roberts, ES; Roycroft, L; Speranza, C; Steffan, J | 1 |
| Birckel, P; Navarro, C; Séguy, L; Vila, M | 1 |
| Doucette, K; Linek, M; Löwenstein, C; Mueller, RS; Müller, MR; Röthig, A; Thorstensen, K | 1 |
| Bruijnzeel-Koomen, CAF; De Bruin-Weller, MS; Hijnen, DJ; Thijs, JL; Van Den Broek, MP; Van Der Geest, BAM; Van Der Schaft, J; Van Schaik, RH; Van Seggelen, WO | 1 |
| Kamata, Y; Takamori, K; Tominaga, M | 1 |
| Fujimura, M; Ishimaru, H; Nakatsuji, Y | 1 |
| Correa da Rosa, J; Dhingra, N; Garcet, S; Gonzalez, J; Guttman-Yassky, E; Krueger, JG; Shemer, A; Suarez-Farinas, M; Ungar, B | 1 |
| Tan, SH; Yew, YW | 1 |
| Chan, YC; Chandran, NS; Ho, MS; Koh, MJ; Lim, YL; Tang, MB; Tay, YK; Thirumoorthy, T | 1 |
| Deleuran, MS; Hjuler, KF; Iversen, L; Jakobsen, L; Olsen, M; Riis, JL; Vestergaard, C | 1 |
| Cordoro, K; Eichenfield, LF; Flohr, C; Lara-Corrales, I; Logan, K; Paller, AS; Proudfoot, L; Schmitt, J; Siegfried, E; Sugarman, J; Tom, W; Totri, CR | 1 |
| Abraham, S; Augustin, M; Bieber, T; Elsner, P; Fölster-Holst, R; Homey, B; Kleinheinz, A; Novak, N; Schmitt, J; Stephan, V; Sticherling, M; Trautmann, F; Weidinger, S; Werfel, T | 1 |
| Aparicio-López, C; Bernardino-Cuesta, B; de Lucas-Collantes, C; Hernández-Martín, A; Noguera-Morel, L; Pérez-Martin, MA; Torrelo, A | 1 |
| Chong, JH; Koh, MJA | 1 |
| Jedlickova, B; Prusa, R; Segethova, J; Tesfaye, H | 1 |
| Dondi, A; Masi, M; Patrizi, A; Ricci, G | 1 |
| Baumgrass, R; Brandt, C; Pavlovic, V; Radbruch, A; Worm, M | 1 |
| Burkhart, CN; Morrell, DS; Shaw, MG | 1 |
| Jang, DJ; Kim, CK; Kim, JH; Kim, ST; Lee, KM; Lee, SY; Lim, JS; Lim, SJ; Park, JY | 1 |
| Bruijnzeel-Koomen, CA; de Bruin-Weller, MS; Haeck, I; Hijnen, D; Knol, EF; Nijhuis, E; van Kraats, AA | 1 |
| Bruijnzeel-Koomen, CA; Haeck, IM; Van Velsen, SG | 1 |
| Kang, MJ; Kim, HO; Kim, HS; Park, YM | 1 |
| Albouy, M; Boulet, M; Carlotti, DN; Ducret, J; Jasmin, P; Machicote, G; Rème, CA | 1 |
| Goldman, C; Hauptman, J; Petersen, A; Rosser, E | 1 |
| DeBoer, DJ; Favrot, C; Jackson, HA; Mueller, RS; Nuttall, T; Olivry, T; Prélaud, P | 1 |
| Abdollahnia, M; Baumgrass, R; Brandt, C; Wegner, F; Worm, M | 1 |
| Rosenkrantz, WS; Roycroft, LM; Wilson, LS | 1 |
| Bielory, B; Bielory, L | 1 |
| Asai, S; Inagaki, N; Ito, T; Kato, H; Nagai, H; Tanaka, H; Yamashita, H | 1 |
| Bruijnzeel-Koomen, C; de Bruin-Weller, MS; Haeck, IM; Knol, EF; Knol, MJ; Kwakkel-van Erp, JM; Lammers, JW; Otten, HG; Paantjens, AW; van de Graaf, EA; van Ginkel, WG | 1 |
| Calder, V; Dart, JK; Guglielmetti, S | 1 |
| Bruijnzeel-Koomen, CA; de Bruin-Weller, MS; de Vroede, MA; de Wit, TC; Haeck, IM; Knol, MJ; Lam, MG; Pasmans, SG; van Eijk, RL; van Velsen, SG | 1 |
| Mansfield, CS; Paul, AE; Thompson, M | 1 |
| Bronsvoort, BM; Evans, H; Handel, IG; Kovalik, M; Mellanby, RJ; Thoday, KL; van den Broek, AH | 1 |
| Hashimoto, Y; Iizuka, H; Mizumoto, T; Nakamura, S; Nishi, K; Takahashi, H; Takeda, K | 1 |
| Hirasawa, N; Ohuchi, K | 1 |
| Taszkun, I | 1 |
| Bruijnzeel-Koomen, CA; de Bruin-Weller, MS; Haeck, IM; Knol, MJ; Ten Berge, O; van Velsen, SG | 1 |
| Kovalik, M; Kozak, M; Palenik, L; Pomorska, D; Pomorski, Z; Shaw, DJ; Szczepanik, M; Taszkun, I; Thoday, KL; van den Broek, AH; Wilkolek, P | 1 |
| Simon, D | 1 |
| Frangos, JE; Frankel, HC; Qureshi, AA | 1 |
| Barańska-Rybak, W; Cegielska, A; Gniadecki, R; Lugowska-Umer, H; Sokołowska-Wojdyło, M; Trzeciak, M | 1 |
| Bensignor, E; Cornegliani, L; Löwenstein, C; McEwan, NA; Nuttall, TJ; Rème, CA | 1 |
| Evans, H; Kovalik, M; Mellanby, RJ; Thoday, KL; van den Broek, AH | 1 |
| Fujisawa, T; Ikeda, T; Seishima, M; Shu, E | 1 |
| de-la-Cuadra-Oyanguren, J; Esteve-Martínez, A; García-Rabasco, A; Miralles, J | 1 |
| Chavarría Mur, E; Mauleón Fernández, C; Silvente San Nicasio, C; Valdivielso Ramos, M | 1 |
| Alvarez-López, M; Casas Asuncion, E; Moreno, JC; Puya, R; Velez, A | 1 |
| Kim, ME; Nahm, DH | 1 |
| Arkwright, PD; Beaumont, DR | 1 |
| Bruijnzeel-Koomen, CA; de Bruin-Weller, MS; Giovannone, B; Haeck, IM; Hijnen, D; Knol, EF; Knol, MJ; Laaper-Ertmann, M; Nijhuis, E; van Kraats, AA | 1 |
| Beck, LA; Denby, KS | 1 |
| Forster, SL; Olivry, T; Seewald, W; Steffan, J | 1 |
| Abuchar, A; Dehesa, L; Kerdel, FA; Nuno-Gonzalez, A; Vitiello, M | 1 |
| Georgas, D; Hoffmann, K; Schempp, CM; Tomi, NS; Wolf, P | 1 |
| Feldman, SR | 1 |
| Gonzalez, ME; Tan, AU | 1 |
| Berry, J; Evans, H; Kovalik, M; Mellanby, RJ; Thoday, KL; van den Broek, AH | 1 |
| Palmeiro, BS | 1 |
| Eassa, B; El-Khalawany, MA; Ghonaim, N; Hassan, H; Shaaban, D | 1 |
| Ahn, BJ; Cheong, KA; Choi, Y; Jin, SY; Kwon, HB; Lee, AY; Lee, J | 1 |
| Cheong, KA; Choi, YS; Kim, CH; Lee, AY | 1 |
| Jin, J; Wei, J; Xu, H; Zhang, J; Zhang, Y | 1 |
| Fernández-López, E; Mir-Bonafé, JM; Palacios-Álvarez, I; Román-Curto, C; Santos-Briz, A; Santos-Durán, JC | 1 |
| Blewitt, RW; Kirby, B; Owen, CM; Yates, VM | 1 |
| Carlotti, DN; Fisch, RD; Fontaine, J; Guaguère, E; Olivry, T; Prélaud, P; Steffan, J | 1 |
| Gibbon, GW; Klaustermeyer, WB; Yu, FC | 1 |
| Moreno, JC; Ocaña, MS; Vélez, A | 1 |
| Meggitt, SJ; Reynolds, NJ | 1 |
| Alexander, D; Brovedani, F; Fisch, RD; Steffan, J | 1 |
| Mueller, RS; Olivry, T | 1 |
| Breuer, K; Heratizadeh, A; Kapp, A; Werfel, T | 1 |
| Guaguère, E; Olivry, T; Steffan, J | 1 |
| Corrocher, R; Di Lorenzo, G; Mansueto, P; Martinelli, N; Pacor, ML; Rini, GB | 1 |
| Giam, YC; Lee, SS; Tan, AW | 1 |
| Akiba, H; Furukawa, H; Kaneko, F; Nakamura, K; Nishibu, A; Oyama, N; Saeki, H; Tamaki, K; Tojo, M; Tsunemi, Y; Zheng, X | 1 |
| Ferrer, L; Fondati, A; Gruet, P; Horn, J; Noli, C; Steffan, J; Strehlau, G | 1 |
| Erkko, P; Granlund, H; Nuutinen, M; Pekurinen, M; Reitamo, S; Salo, H | 1 |
| Galipeau, L; Last, RD; Lindsay, D; Manning, T; Suzuki, Y; Whitbread, TJ | 1 |
| La Rosa, M; Leonardi, S; Marchese, G; Miraglia Del Giudice, M; Rotolo, N | 1 |
| Maurer, M; Rohlfs, A; Steffan, J; Strehlau, G | 1 |
| Natarajan, S; Sinha, A; Velangi, S | 1 |
| Choi, SO; Hong, SJ; Jang, SO; Kim, BS; Kim, JH; Lee, SY; Seo, HJ; Shim, JY | 1 |
| Power, HT; Radowicz, SN | 1 |
| Ovadia, S; Wilson, SR; Zeiss, CJ | 1 |
| Parks, C; Seewald, W; Steffan, J | 1 |
| Laube, S; Smith, AG; Stephens, M; Tan, BB; Whittaker, SJ | 1 |
| Bassett, R; Bryden, S; Burrows, A; Burton, G; Hill, A; Robson, D; Walker, R | 1 |
| Bernier, C | 1 |
| Meggitt, SJ; Wahie, S | 1 |
| Favrot, C; Mueller, R; Steffan, J | 1 |
| Barandica, L; Brazís, P; Church, MK; Clough, GF; García, F; Puigdemont, A | 1 |
| Dijkmans, BA; Finlay, AY; Griffiths, CE; Ho, VC; Johnston, A; Katsambas, A; Luger, TA; Mrowietz, U; Thestrup-Pedersen, K | 1 |
| Hashimoto, S; Kaneko, F; Nakamura, K; Oyama, N; Saeki, H; Tamaki, K; Tsunemi, Y | 1 |
| Balme, B; Dalle, S; Houot, R; Mougel, F; Thomas, L | 1 |
| Linek, M; Mueller, RS; Peters, S; Stechmann, K; Steffan, J; Thelen, A | 1 |
| Bruijnzeel-Koomen, CA; de Bruin-Weller, MS; Hijnen, DJ; ten Berge, O; Timmer-de Mik, L | 1 |
| Bäumer, W; Kietzmann, M | 1 |
| Meurer, M; Schmitt, J; Schmitt, N | 1 |
| Bruijnzeel-Koomen, C; de Bruin-Weller, M; Hijnen, DJ; Knol, E | 1 |
| Shimazaki, J; Shimmura, S; Tomita, M; Tsubota, K | 1 |
| Bianchi, L; Campione, E; Chimenti, S; Diluvio, L; Giorgetti, G; Paternò, EJ | 1 |
| Willemse, T; Wisselink, MA | 1 |
| Ortiz de Frutos, FJ | 1 |
| Wong, SS | 1 |
| Hori, Y; Imayama, S; Koga, T; Kubota, Y | 1 |
| Camp, RD; Friedmann, PS; Heule, F; Ho, V; Reitamo, S | 1 |
| Cooper, A; Lee, ML; Stephens, RB | 1 |
| Erkko, P; Granlund, H; Reitamo, S; Sinisalo, M | 1 |
| Nagashima, M; Sagawa, Y; Shiohara, T | 1 |
| Califano, L; Cannavò, SP; Guarneri, B; Vaccaro, M | 1 |
| Kemp, AS; Tang, ML | 1 |
| Friedmann, PS; Levell, NJ; Munro, CS; Shuster, S | 1 |
| Heule, F; Korstanje, M; Stenveld, HJ; van den Broek, MJ; van Joost, T; van Vloten, WA | 1 |
| Allen, BR; Berth-Jones, J; Camp, RD; Finlay, AY; Graham-Brown, RA; Khan, GK; Luscombe, DK; Marks, R; Motley, RJ; Salek, MS | 1 |
| Kemp, A; Tang, M | 1 |
| Fritsch, PO; Sepp, N | 1 |
| Hamasaki, Y; Ishii, E; Miyazaki, S; Sakai, R; Yamamoto, S | 1 |
| Allen, BR; Berth-Jones, J; Bleehen, SS; Cork, MJ; Finlay, AY; Goodyear, H; Graham-Brown, RA; Lewis-Jones, S; Salek, MS; Smith, S; Tan, B; Zaki, I | 1 |
| Zachariae, H | 1 |
| Berth-Jones, J; Bourke, JF; Graham-Brown, RA; Holder, J | 1 |
| Hellewell, PG; Teixeira, MM; Williams, TJ | 1 |
| Cappelli, G; Caproni, M; D'Agata, A; Fabbri, P | 1 |
| Ali, M; Chawla, M; Marks, R | 1 |
| Beljaards, RC; Bos, JD; De Rie, MA; Van Der Rhee, HJ; Wuite, J; Zeegelaar, J; Zonneveld, IM | 1 |
| Allen, BR; Emerson, R; Zaki, I | 1 |
| Adriaans, B; Allen, BR; Archer, CB; Berth-Jones, J; Camp, RD; Douglas, WS; English, JS; Freeman, K; Friedmann, PS; Graham-Brown, RA; Holden, CA; Lewis-Jones, MS; Marks, R; Oliwiecki, S; Rogers, SC | 1 |
| Hunziker, T | 1 |
| Bakos, N; Szemere, P | 1 |
| Gonzalez-Otero, F | 1 |
| Campbell, DE; Kemp, AS | 1 |
| Hannouche, D; Hoang-Xuan, T; Prisant, O; Robin, H | 1 |
| Granlund, H; Reitamo, S | 1 |
| Erkko, P; Granlund, H; Reitamo, S | 1 |
| Cornil, F; Piérard, GE; Piérard-Franchimont, C; Stas, I; Willemaers, V | 1 |
| Morohashi, M; Toyoda, M | 1 |
| Cook, LJ; Thomas, MD | 1 |
| Atakan, N; Erdem, C | 1 |
| Cachelin, AB; Kägi, MK; Wili, PB; Wüthrich, B; Zurbriggen, B | 1 |
| Joller-Jemelka, H; Kägi, MK; Wüthrich, B | 1 |
| de la Brassinne, M; Degreef, H; Heenen, M; Lachapelle, JM; Lambert, J; Naeyaert, JM | 1 |
| Bottari, V; De Pità, O; Fontana, L; Frezzolini, A; Puddu, P; Ruffelli, M | 1 |
| Chihara, J; Kurashimo, S; Matsukura, M; Tezuka, T; Yamada, H; Yudate, T | 1 |
| Möller, M; Reinhard, T; Sundmacher, R | 1 |
| Ahmed, I; Barclay, G; Beard, AL; Berth-Jones, J; Cork, MJ; Finlay, AY; Graham-Brown, RA; Harper, JI; Hoeger, P; Lacour, M; Sowden, JM; Sumner, MJ; Wilson, NJ | 1 |
| Bräutigam, M; Czech, W; Schöpf, E; Weidinger, G | 1 |
| Brazzini, B; Caproni, M; Cardinali, C; Fabbri, P; Salvatore, E | 1 |
| Bieber, T; Bornhövd, EC; Schuller, E; Wollenberg, A | 1 |
| Antrobus, P; Chapel, HM; Farrell, AM; Ferry, BL; Powell, S; Simpson, D | 1 |
| Lee, TH | 1 |
| Bangert, J; Behr, FD; Levine, N | 1 |
| Fontaine, J; Olivry, T | 1 |
| Biasi, D; Carletto, A; Corrocher, R; Di Lorenzo, G; Pacor, ML | 1 |
| Berth-Jones, J; Camp, RD; Dillon, MJ; Finlay, AY; Harper, JI; Holden, CA; O'Sullivan, D; Veys, PA | 1 |
| Bräutigam, M; Bunikowski, R; Kussebi, F; Renz, H; Staab, D; Wahn, U; Weidinger, G | 1 |
| Bräutigam, M; Bunikowski, R; Gerhold, K; Hamelmann, E; Renz, H; Wahn, U | 1 |
| Bornhövd, E; Burgdorf, WH; Wollenberg, A | 1 |
| Askenase, PW; Geba, GP; Ptak, W | 1 |
| Akdis, CA; Akdis, M; Blaser, K; Bröcker, EB; Disch, R; Schmid-Grendelmeier, P; Trautmann, A | 1 |
| Duvic, M; Jones, D; Pielop, JA | 1 |
| Kinaciyan, T; Kraft, D; Natter, S; Stingl, G; Valenta, R | 1 |
| Davidson, G; Jackson, HA; Murphy, KM; Olivry, T; Rivierre, C; Sousa, CA | 1 |
| Ardigò, M; Borroni, G; Borroni, RG; Brazzelli, V; Chiesa, MG; Prestinari, F | 1 |
| Ahmed, I; Milford, DV; Moss, C | 1 |
| de Prost, Y | 2 |
| Ikari, Y; Kawaguchi, K; Mizoguchi, M; Mizushima, Y; Ohsuga, Y; Yanagawa, A | 1 |
| Stütz, A | 1 |
| Reinhard, T; Sundmacher, R | 1 |
| Peter, RU; Ruzicka, T | 1 |
| Kozel, MM; Prens, EP; Tank, B; Troost, R; van Joost, T | 1 |
| Barth, J | 1 |
| Korstanje, MJ; van de Staak, WJ | 1 |
| Bos, JD; De Rie, MA; Meinardi, MM | 1 |
| Wahlgren, CF | 1 |
| Daly, BM; Friedmann, PS; Higgins, EM; Marks, JM; Munro, CS; Shuster, S | 1 |
| Ellis, CN; Griffiths, CE; Groisser, DS; Voorhees, JJ | 1 |
61 review(s) available for cyclosporine and Dermatitis, Atopic
| Article | Year |
|---|---|
The evolving atopic dermatitis management landscape.
Topics: Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Eczema; Humans; Janus Kinase Inhibitors | 2022 |
Review of Tralokinumab in the Treatment of Atopic Dermatitis.
Topics: Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Double-Blind Method; Glucocorticoids; Humans; Immunoglobulin A; Interleukin-13; Severity of Illness Index; Treatment Outcome | 2023 |
Clinical phenotypes of adult atopic dermatitis and related therapies.
Topics: Alitretinoin; Cyclosporine; Dermatitis, Atopic; Humans; Phenotype; Prurigo; Severity of Illness Index; Treatment Outcome | 2022 |
Treatment options for moderate to severe atopic dermatitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Biological Products; Cyclosporine; Dermatitis, Atopic; Humans | 2022 |
Expert consensus on the systemic treatment of atopic dermatitis in special populations.
Topics: Aged; Asthma; Cyclosporine; Dermatitis, Atopic; Female; Humans; Methotrexate; Mycophenolic Acid | 2023 |
Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies.
Topics: Biological Therapy; Cyclosporine; Dermatitis, Atopic; Europe; Humans; Immunosuppressive Agents | 2023 |
Monitoring trough levels in cyclosporine for atopic dermatitis: A systematic review.
Topics: Child; Cyclosporine; Dermatitis, Atopic; Drug Administration Schedule; Drug Monitoring; Humans; Immunosuppressive Agents; Kidney Diseases | 2019 |
Comparing cutaneous molecular improvement with different treatments in atopic dermatitis patients.
Topics: Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Cyclosporine; Cytokines; Dermatitis, Atopic; Humans; Skin; Th2 Cells; Tissue Array Analysis; Transcriptome | 2020 |
Pharmacological management of atopic dermatitis in the elderly.
Topics: Aged; Antibodies, Monoclonal, Humanized; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Calcineurin Inhibitors; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Humans; Pain; Pruritus; Treatment Outcome | 2020 |
Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Humans; Immunologic Factors; Methotrexate; Network Meta-Analysis; Pruritus; Quality of Life; Severity of Illness Index; Treatment Outcome | 2020 |
What's new in atopic eczema? An analysis of systematic reviews published in 2018. Part 2: systemic therapies.
Topics: Acetates; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Therapy; Child; Complementary Therapies; Cyclopropanes; Cyclosporine; Cytochrome P-450 CYP1A2 Inducers; Dermatitis, Atopic; Eczema; Humans; Immunosuppressive Agents; Janus Kinase Inhibitors; Naltrexone; Narcotic Antagonists; Omalizumab; Placebo Effect; Probiotics; Quinolines; Sulfides; Ustekinumab; Vitamin D | 2020 |
Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adult; Cyclosporine; Dermatitis, Atopic; Eczema; Humans | 2021 |
Current treatments for atopic dermatitis in Japan.
Topics: Aged; Cyclosporine; Dermatitis, Atopic; Humans; Japan; Tacrolimus; Treatment Outcome | 2021 |
Treatment of the feline atopic syndrome - a systematic review.
Topics: Allergens; Animals; Cat Diseases; Cats; Cyclosporine; Dermatitis, Atopic; Desensitization, Immunologic; Glucocorticoids; Immunotherapy; Retrospective Studies; Syndrome | 2021 |
Long-Term Treatment of Atopic Dermatitis.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Azathioprine; Baths; Calcineurin Inhibitors; Cyclosporine; Dermatitis, Atopic; Glucocorticoids; Humans; Immunosuppressive Agents; Methotrexate; Mycophenolic Acid; Phototherapy; Randomized Controlled Trials as Topic; Skin Cream; Time Factors | 2017 |
Special Considerations for Therapy of Pediatric Atopic Dermatitis.
Topics: Administration, Cutaneous; Adolescent; Adrenal Cortex Hormones; Child; Child, Preschool; Comorbidity; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Emollients; Humans; Infant | 2017 |
Adjunctive Management of Itch in Atopic Dermatitis.
Topics: Acupuncture Therapy; Administration, Cutaneous; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Calcineurin Inhibitors; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dietary Supplements; Emollients; Enzyme Inhibitors; Histamine Antagonists; Humans; Immunosuppressive Agents; Mycophenolic Acid; Neurotransmitter Agents; Plant Oils; Pruritus; Ultraviolet Therapy | 2017 |
Atopic dermatitis: phototherapy and systemic therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Humans; Immunosuppressive Agents; Interleukin-13; Interleukin-4; Methotrexate; Mycophenolic Acid; Phototherapy | 2017 |
[New aspects in systemic treatment of atopic dermatitis].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatitis, Atopic; Glucocorticoids; Humans; Interleukins; Janus Kinase Inhibitors; Off-Label Use; Receptors, Histamine H4; Receptors, Interleukin-13 | 2018 |
Systemic Treatment for Severe Atopic Dermatitis.
Topics: Administration, Intravenous; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Child; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Immunotherapy; Quality of Life; Receptors, Interleukin-4; Skin | 2019 |
What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 1: treatment and prevention.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Anti-Allergic Agents; Azathioprine; Calcineurin Inhibitors; Child, Preschool; Complementary Therapies; Cyclosporine; Dermatitis, Atopic; Dietary Fats; Glycyrrhetinic Acid; Humans; Immunosuppressive Agents; Infant; Infant, Newborn; Omalizumab; Plant Extracts; Ultraviolet Therapy; Vitamin D | 2019 |
Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?
Topics: Azathioprine; Cyclosporine; Dermatitis, Atopic; Humans; Methotrexate; Randomized Controlled Trials as Topic | 2019 |
Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review.
Topics: Azathioprine; Cyclosporine; Dermatitis, Atopic; Glucocorticoids; Humans; Immunosuppressive Agents; Interferon-gamma; Methotrexate; Mycophenolic Acid | 2014 |
Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis.
Topics: Animals; Chronic Disease; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Immunosuppressive Agents; Safety; Treatment Outcome | 2014 |
Ciclosporin 10 years on: indications and efficacy.
Topics: Animals; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Immunosuppressive Agents; Treatment Outcome; Veterinary Medicine | 2014 |
Child with atopic dermatitis.
Topics: Administration, Topical; Animals; Antigens, Dermatophagoides; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Desensitization, Immunologic; Eczema; Edema; Humans; Immunoglobulin E; Male; Pyroglyphidae; Tacrolimus | 2015 |
Systemic Agents for Severe Atopic Dermatitis in Children.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Child; Cyclosporine; Dermatitis, Atopic; Drug Administration Routes; Humans; Immunosuppressive Agents; Methotrexate; Mycophenolic Acid; Severity of Illness Index; Thalidomide | 2015 |
Itch in Atopic Dermatitis Management.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aprepitant; Calcineurin Inhibitors; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Emollients; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Phototherapy; Pruritus | 2016 |
Guidelines for the Management of Atopic Dermatitis in Singapore.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Anti-Bacterial Agents; Azathioprine; Calcineurin Inhibitors; Coinfection; Cyclosporine; Dermatitis, Atopic; Dermatology; Disease Management; Emollients; Food Hypersensitivity; Humans; Immunosuppressive Agents; Methotrexate; Patient Education as Topic; Phototherapy; Practice Guidelines as Topic; Referral and Consultation; Severity of Illness Index; Singapore | 2016 |
Non-topical management of recalcitrant paediatric atopic dermatitis.
Topics: Azathioprine; Child; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Humans; Immunosuppressive Agents; Medicine, Chinese Traditional; Methotrexate; Mycophenolic Acid; Phototherapy; Prebiotics; Probiotics; Recurrence; Ultraviolet Therapy | 2017 |
Systemic therapy of atopic dermatitis in children.
Topics: Adrenal Cortex Hormones; Anti-Allergic Agents; Antibodies, Monoclonal; Child; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Histamine Antagonists; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents | 2009 |
Systemic therapies for pediatric atopic dermatitis: a review for the primary care physician.
Topics: Algorithms; Anti-Bacterial Agents; Antiviral Agents; Azathioprine; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Emollients; Glucocorticoids; Histamine Antagonists; Humans; Immunoglobulins; Immunologic Factors; Infant; Infusions, Intravenous; Interferon-gamma; Methotrexate; Mycophenolic Acid; Phototherapy; Primary Health Care; Severity of Illness Index; Treatment Outcome | 2009 |
Atopic dermatitis and keratoconjunctivitis.
Topics: Adrenal Cortex Hormones; Animals; Blepharitis; Cyclosporine; Dermatitis, Atopic; Humans; Immunomodulation; Keratoconjunctivitis; Risk Factors; Tacrolimus | 2010 |
Atopic keratoconjunctivitis and atopic dermatitis.
Topics: Basophils; Conjunctivitis, Allergic; Cyclosporine; Cytokines; Dermatitis, Atopic; Drug Resistance; Eosinophils; Epithelial Cells; Humans; Interleukin-33; Interleukins; Keratoconjunctivitis; Tacrolimus; Thymic Stromal Lymphopoietin | 2010 |
[Roles of histamine in the exacerbated allergic dermatitis].
Topics: Animals; Cyclosporine; Dermatitis, Atopic; Disease Models, Animal; Drug Therapy, Combination; Histamine; Histamine Antagonists; Humans; Mice; Picryl Chloride; Piperidines; Pyrilamine; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H1; Receptors, Histamine H3; Receptors, Histamine H4; Tetradecanoylphorbol Acetate | 2011 |
Systemic therapy of atopic dermatitis in children and adults.
Topics: Adrenal Cortex Hormones; Adult; Alitretinoin; Antibodies, Monoclonal; Azathioprine; Child; Cyclosporine; Dermatitis, Atopic; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Interferon-gamma; Methotrexate; Mycophenolic Acid; Recombinant Proteins; Tretinoin | 2011 |
Update on systemic therapies for atopic dermatitis.
Topics: Azathioprine; Cyclosporine; Dermatitis, Atopic; Enzyme Inhibitors; Female; Humans; Immunosuppressive Agents; Kaposi Varicelliform Eruption; Male; Methotrexate; Mycophenolic Acid; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
The use of cyclosporine in dermatology.
Topics: Chronic Disease; Cyclosporine; Dermatitis, Atopic; Dermatomyositis; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Prurigo; Psoriasis; Pyoderma Gangrenosum; Skin Diseases; Sweet Syndrome; Urticaria | 2012 |
Management of severe atopic dermatitis in children.
Topics: Administration, Cutaneous; Adolescent; Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Baths; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Disinfectants; Humans; Immunosuppressive Agents; Infant; Methotrexate; Mycophenolic Acid; Sodium Hypochlorite; Ultraviolet Therapy | 2012 |
Cyclosporine in veterinary dermatology.
Topics: Animals; Cat Diseases; Cats; Cyclosporine; Dermatitis, Allergic Contact; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Drug Interactions; Treatment Outcome | 2013 |
Phototherapy and systemic treatments.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Drugs, Chinese Herbal; Humans; Immunosuppressive Agents; Infant; Infant, Newborn; Interferon-gamma; Phototherapy; Steroids; Thymopentin | 2002 |
Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis.
Topics: Administration, Oral; Animals; Cost-Benefit Analysis; Cyclosporine; Dermatitis, Atopic; Dermatology; Dog Diseases; Dogs; Evidence-Based Medicine; Glucocorticoids; Practice Guidelines as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Veterinary Medicine | 2003 |
[Systemic therapy of atopic dermatitis].
Topics: Adjuvants, Immunologic; Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Animals; Anti-Bacterial Agents; Anti-Infective Agents, Local; Antifungal Agents; Azathioprine; Child; Child, Preschool; Cross-Over Studies; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Desensitization, Immunologic; Disease Models, Animal; Double-Blind Method; Histamine Antagonists; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Infant; Leukotriene Antagonists; Medicine, Chinese Traditional; Mice; Mice, Nude; Mycophenolic Acid; Ointments; Photopheresis; Phototherapy; Placebos; Probiotics; PUVA Therapy; Randomized Controlled Trials as Topic; Ultraviolet Therapy | 2003 |
Cyclosporin A: a new drug in the field of canine dermatology.
Topics: Administration, Oral; Animals; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Humans; Infusions, Intravenous; Randomized Controlled Trials as Topic; Rectal Fistula | 2004 |
Lymphomatoid papulosis in a patient with atopic eczema on long-term ciclosporin therapy.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Lymphomatoid Papulosis; Male; Methotrexate | 2005 |
[How should severe and chronic atopic dermatitis be managed in children?].
Topics: Azathioprine; Child; Chronic Disease; Cyclosporine; Dermatitis, Atopic; Humans; Immunologic Factors; Immunosuppressive Agents; PUVA Therapy; Severity of Illness Index | 2005 |
A systematic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs.
Topics: Animals; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Safety; Severity of Illness Index; Treatment Outcome | 2006 |
Update on the use of ciclosporin in immune-mediated dermatoses.
Topics: Arthritis, Psoriatic; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Patient Selection; Psoriasis; Quality of Life; Skin Diseases; Skin Diseases, Papulosquamous | 2006 |
Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis.
Topics: Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents | 2007 |
[Atopic dermatitis and tacrolimus in adults].
Topics: Adrenal Cortex Hormones; Adult; Child; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Meta-Analysis as Topic; Middle Aged; Neoplasms; Pruritus; Retrospective Studies; Spain; Tacrolimus; Young Adult | 2008 |
Cyclosporin treatment of atopic dermatitis: five case studies and literature review.
Topics: Adolescent; Adult; Cyclosporine; Dermatitis, Atopic; Female; Humans; Male; Middle Aged; Severity of Illness Index; Treatment Outcome | 1994 |
[Atopic dermatitis].
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Desensitization, Immunologic; Glucocorticoids; Humans; Immunosuppressive Agents; Infant; Phenotype; Ultraviolet Therapy | 1997 |
[Atopic eczema: is the treatment practice based on research results?].
Topics: Adrenal Cortex Hormones; Adult; Child; Cyclosporine; Dermatitis, Atopic; Food Hypersensitivity; Humans; Research; Treatment Outcome; Ultraviolet Therapy | 1995 |
Cyclosporin in atopic dermatitis: review of the literature and outline of a Belgian consensus.
Topics: Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents | 1999 |
Cyclosporin for atopic dermatitis in children.
Topics: Child; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Drug Monitoring; Humans; Immunosuppressive Agents | 2001 |
Macrolactam immunomodulators for topical treatment of inflammatory skin diseases.
Topics: Administration, Topical; Clinical Trials as Topic; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Inflammation; Sirolimus; Skin Diseases; Tacrolimus | 2001 |
Management of severe atopic dermatitis.
Topics: Cyclosporine; Dermatitis, Atopic; Humans; Interferons; Interleukins; Photochemotherapy; PUVA Therapy; Thymus Hormones | 1992 |
Immunosuppressive macrolides.
Topics: Animals; Anti-Bacterial Agents; Carrier Proteins; Cyclosporine; Dermatitis, Atopic; Dermatitis, Contact; Disease Models, Animal; Guinea Pigs; Immunosuppressive Agents; Mice; Polyenes; Receptors, Drug; Receptors, Immunologic; Sirolimus; Swine; Tacrolimus; Tacrolimus Binding Proteins | 1992 |
[Cyclosporin A in the therapy of inflammatory dermatoses].
Topics: Behcet Syndrome; Cyclosporine; Dermatitis; Dermatitis, Atopic; Humans; Lichen Planus; Photosensitivity Disorders; Psoriasis; Pyoderma Gangrenosum; Scleroderma, Localized | 1992 |
Atopic dermatitis: recent therapeutic advances.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Dermatomycoses; Female; Humans; Interferon-alpha; Interferon-gamma; Interleukin-2; Recombinant Proteins; Thymus Hormones | 1992 |
A review and update of the clinical uses of cyclosporine in dermatology.
Topics: Alopecia; Cyclosporine; Dermatitis, Atopic; Dermatology; Humans; Lichen Planus; Mycosis Fungoides; Pemphigus; Psoriasis; Skin Diseases | 1991 |
68 trial(s) available for cyclosporine and Dermatitis, Atopic
| Article | Year |
|---|---|
Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7).
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Double-Blind Method; Eczema; Glucocorticoids; Humans; Severity of Illness Index; Treatment Outcome | 2022 |
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, p
Topics: Adrenal Cortex Hormones; Azetidines; Contraindications; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Double-Blind Method; Headache; Herpes Simplex; Humans; Influenza, Human; Nasopharyngitis; Purines; Pyrazoles; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2022 |
Comparison of whole blood concentrations of oral human generic modified ciclosporin capsules with microemulsified ciclosporin capsules approved for canine atopic dermatitis following a single oral administration to healthy dogs.
Topics: Administration, Oral; Animals; Cross-Over Studies; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Male; Veterinary Drugs | 2023 |
IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Double-Blind Method; Humans; Immunosuppressive Agents; Omalizumab; Severity of Illness Index; Treatment Outcome | 2023 |
Identifying biomarkers of treatment response to ciclosporin in atopic dermatitis through multiomic predictive modelling: DERMATOMICS study protocol.
Topics: Biomarkers; Clinical Trials, Phase IV as Topic; Cyclosporine; Dermatitis, Atopic; Humans; Multiomics; Retrospective Studies | 2023 |
A single-centre prospective study comparing efficacy and safety of apremilast with cyclosporine in moderate to severe atopic dermatitis.
Topics: Cyclosporine; Dermatitis, Atopic; Double-Blind Method; Humans; Immunoglobulin A; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2023 |
Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial.
Topics: Adolescent; Child; Cyclosporine; Dermatitis, Atopic; Double-Blind Method; Filaggrin Proteins; Humans; Methotrexate; Odds Ratio; Severity of Illness Index; Treatment Outcome | 2023 |
A double-blinded, randomized, controlled, crossover evaluation of a zinc methionine supplement as an adjunctive treatment for canine atopic dermatitis.
Topics: Animals; Biotin; Cross-Over Studies; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dietary Supplements; Dog Diseases; Dogs; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Essential; Female; Male; Methionine; Organometallic Compounds | 2017 |
A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis.
Topics: Animals; Antibodies, Monoclonal; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Female; Immunosuppressive Agents; Interleukins; Male | 2017 |
Subcutaneous administration of ciclosporin in 11 allergic cats - a pilot open-label uncontrolled clinical trial.
Topics: Animals; Cat Diseases; Cats; Cyclosporine; Dermatitis, Atopic; Female; Hypersensitivity; Male; Pilot Projects; Prospective Studies; Pruritus; Skin Diseases; Subcutaneous Absorption | 2018 |
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t
Topics: Administration, Cutaneous; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Treatment Outcome; Young Adult | 2018 |
Single blinded, randomized, placebo-controlled study on the effects of ciclosporin on cutaneous barrier function and immunological response in atopic beagles.
Topics: Animals; Antimicrobial Cationic Peptides; Caspase 14; Cyclophilins; Cyclosporine; Cytokines; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Filaggrin Proteins; Intermediate Filament Proteins; Random Allocation; Single-Blind Method; Skin; Thymic Stromal Lymphopoietin; Transforming Growth Factors; Tumor Necrosis Factor-alpha | 2018 |
A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT).
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Cost-Benefit Analysis; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Female; Filaggrin Proteins; Humans; Intermediate Filament Proteins; Male; Methotrexate; Multicenter Studies as Topic; Pragmatic Clinical Trials as Topic; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2018 |
Efficacy of a new topical cyclosporine A formulation in the treatment of atopic dermatitis in dogs.
Topics: Administration, Topical; Animals; Chemistry, Pharmaceutical; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Double-Blind Method; Female; Male | 2013 |
Concurrent short-term use of prednisolone with cyclosporine A accelerates pruritus reduction and improvement in clinical scoring in dogs with atopic dermatitis.
Topics: Animals; Anti-Inflammatory Agents; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Drug Administration Schedule; Drug Therapy, Combination; Female; Immunosuppressive Agents; Male; Prednisolone; Pruritus | 2013 |
Keratoplasty postoperative treatment update.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Cyclosporine; Dermatitis, Atopic; Female; Graft Rejection; Humans; Immunosuppressive Agents; Keratoplasty, Penetrating; Male; Middle Aged; Postoperative Care; Prospective Studies; Tacrolimus; Young Adult | 2013 |
A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.
Topics: Animals; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Female; Male; Pruritus; Pyrimidines; Single-Blind Method; Sulfonamides; Treatment Outcome | 2015 |
The influence of non-specific anti-pruritus treatment with cyclosporine A on transepidermal water loss (TEWL) in natural atopic dermatitis in dogs.
Topics: Animals; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Female; Male; Pruritus; Water Loss, Insensible | 2015 |
Clinical efficacy and safety following dose tapering of ciclosporin in cats with hypersensitivity dermatitis.
Topics: Administration, Oral; Animals; Cat Diseases; Cats; Cyclosporine; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Immunosuppressive Agents; Male; Severity of Illness Index; Treatment Outcome | 2016 |
Confirmatory field study for the evaluation of ciclosporin at a target dose of 7.0 mg/kg (3.2 mg/lb) in the control of feline hypersensitivity dermatitis.
Topics: Animals; Canada; Cat Diseases; Cats; Cyclosporine; Dermatitis, Atopic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Immunosuppressive Agents; Male; Pruritus; Severity of Illness Index; Treatment Outcome; United States | 2016 |
Bioequivalence study between two formulations of ciclosporin A (Cyclavance® oral solution and Atopica® soft capsules) following a single oral administration to dogs.
Topics: Animals; Cross-Over Studies; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Drug Compounding; Male; Random Allocation; Therapeutic Equivalency | 2016 |
Evaluation of cyclosporine-sparing effects of polyunsaturated fatty acids in the treatment of canine atopic dermatitis.
Topics: Animals; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Omega-6; Female; Male | 2016 |
[Severe atopic dermatitis. Antibodies revolutionize therapy].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatitis, Atopic; Humans | 2015 |
Cyclosporin A Treatment in Intrinsic Canine Atopic Dermatitis (Atopic-like Dermatitis): Open Trial Study.
Topics: Animals; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Immunosuppressive Agents | 2016 |
The use of recombinant omega interferon therapy in canine atopic dermatitis: a double-blind controlled study.
Topics: Animals; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Double-Blind Method; Drug Administration Schedule; Female; Immunosuppressive Agents; Interferon Type I; Male; Recombinant Proteins | 2009 |
Investigation on the effects of ciclosporin (Atopica) on intradermal test reactivity and allergen-specific immunoglobulin (IgE) serology in atopic dogs.
Topics: Allergens; Animals; Cross-Over Studies; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Double-Blind Method; Immunoglobulin E; Immunosuppressive Agents; Intradermal Tests | 2010 |
Zinc-carnosine and vitamin E supplementation does not ameliorate gastrointestinal side effects associated with ciclosporin therapy of canine atopic dermatitis.
Topics: Animals; Appetite; Carnosine; Cyclosporine; Dermatitis, Atopic; Diarrhea; Dietary Supplements; Dog Diseases; Dogs; Drug Combinations; Immunosuppressive Agents; Vitamin E; Vomiting; Zinc | 2011 |
Differential usefulness of biomarkers thymus and activation-regulated chemokine and soluble CD30 during enteric coated mycophenolate sodium and cyclosporine therapy in atopic dermatitis.
Topics: Biomarkers; Chemokine CCL17; Cyclosporine; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ki-1 Antigen; Male; Mycophenolic Acid; Observer Variation; Pilot Projects; Prognosis; Sensitivity and Specificity; Severity of Illness Index; Single-Blind Method; Tablets, Enteric-Coated; Treatment Outcome | 2010 |
Ciclosporin A therapy is associated with disturbances in glucose metabolism in dogs with atopic dermatitis.
Topics: Animals; Blood Glucose; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Drug Administration Schedule; Female; Fructosamine; Glucagon; Immunosuppressive Agents; Insulin; Male; Severity of Illness Index; Treatment Outcome | 2011 |
Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial.
Topics: Adult; Chemokine CCL17; Cyclosporine; Dermatitis, Atopic; Enzyme Inhibitors; Female; Humans; Immunoglobulin E; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Tablets, Enteric-Coated | 2011 |
Comparable efficacy of a topical 0.0584% hydrocortisone aceponate spray and oral ciclosporin in treating canine atopic dermatitis.
Topics: Administration, Oral; Administration, Topical; Aerosols; Animals; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Female; Hydrocortisone; Male; Single-Blind Method; Treatment Outcome | 2012 |
Treatment of severe atopic dermatitis with a combination of subcutaneous allergen immunotherapy and cyclosporin.
Topics: Adolescent; Adult; Allergens; Combined Modality Therapy; Cyclosporine; Dermatitis, Atopic; Desensitization, Immunologic; Female; Humans; Immunosuppressive Agents; Injections, Subcutaneous; Male; Severity of Illness Index; Treatment Outcome | 2012 |
Modulation of lymphocyte function in vivo via inhibition of calcineurin or purine synthesis in patients with atopic dermatitis.
Topics: B-Lymphocytes; Calcineurin; Calcineurin Inhibitors; Cyclosporine; Dermatitis, Atopic; DNA-Binding Proteins; Forkhead Transcription Factors; Humans; Intracellular Signaling Peptides and Proteins; Mycophenolic Acid; Nuclear Proteins; Purines; Severity of Illness Index; T-Lymphocytes; Treatment Outcome; Tumor Necrosis Factor alpha-Induced Protein 3 | 2012 |
Responsiveness and validity of the SCORFAD, an extent and severity scale for feline hypersensitivity dermatitis.
Topics: Animals; Cat Diseases; Cats; Cyclosporine; Dermatitis, Atopic; Immunosuppressive Agents; Reproducibility of Results; Sensitivity and Specificity | 2012 |
Extracorporeal photochemotherapy as systemic monotherapy of severe, refractory atopic dermatitis: results from a prospective trial.
Topics: Adult; Alkaline Phosphatase; Cyclosporine; Dermatitis, Atopic; Drug Administration Schedule; Female; Humans; Leukocyte Count; Male; Middle Aged; Photopheresis; Potassium; Prospective Studies; Quality of Life; Steroids; Ultraviolet Rays | 2013 |
Ciclosporin therapy is associated with minimal changes in calcium metabolism in dogs with atopic dermatitis.
Topics: Animals; Calcium; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Female; Homeostasis; Immunosuppressive Agents; Male; Parathyroid Hormone; Vitamin D | 2012 |
Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt.
Topics: Administration, Oral; Adolescent; Child; Cyclosporine; Dermatitis, Atopic; Drug Administration Schedule; Egypt; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Severity of Illness Index; Treatment Outcome | 2013 |
Combination of glucosamine improved therapeutic effect of low-dose cyclosporin A in patients with atopic dermatitis: a pilot study.
Topics: Adolescent; Adult; Cross-Over Studies; Cyclosporine; Dermatitis, Atopic; Drug Therapy, Combination; Female; Glucosamine; Humans; Interferon-gamma; Interleukin-4; Leukocytes, Mononuclear; Linear Models; Male; Pilot Projects; Severity of Illness Index; Young Adult | 2013 |
Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs.
Topics: Administration, Oral; Animals; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Female; Male; Pruritus; Seasons; Severity of Illness Index; Treatment Outcome | 2002 |
Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: a parallel, blinded, randomized controlled trial.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Double-Blind Method; Drug Administration Schedule; Female; Male; Methylprednisolone; Treatment Outcome | 2003 |
Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study.
Topics: Administration, Oral; Adolescent; Adult; Cyclosporine; Dermatitis, Atopic; Double-Blind Method; Drug Administration Schedule; Eosinophils; Female; Humans; Immunoglobulin E; Immunosuppressive Agents; Leukocyte Count; Male; Middle Aged; Ointments; Severity of Illness Index; Tacrolimus | 2004 |
Remission of the clinical signs of atopic dermatitis in dogs after cessation of treatment with cyclosporin A or methylprednisolone.
Topics: Animals; Anti-Inflammatory Agents; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Double-Blind Method; Follow-Up Studies; Methylprednisolone; Pruritus; Recurrence; Risk Factors; Severity of Illness Index; Skin; Treatment Outcome | 2004 |
Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs.
Topics: Administration, Oral; Animals; Capsules; Chromatography, High Pressure Liquid; Cross-Over Studies; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Emulsions; Female; Immunosuppressive Agents; Male; Treatment Outcome | 2004 |
Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis.
Topics: Administration, Oral; Animals; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Male; Pruritus; Safety; Treatment Outcome | 2005 |
Efficacy of cyclosporin in the treatment of atopic dermatitis in dogs--combined results from two veterinary dermatology referral centres.
Topics: Administration, Oral; Animals; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Female; Male; Prospective Studies; Severity of Illness Index; Treatment Outcome; Western Australia | 2004 |
Influence of food intake on the clinical response to cyclosporin A in canine atopic dermatitis.
Topics: Administration, Oral; Animals; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Eating; Germany; Immunosuppressive Agents; Severity of Illness Index; Treatment Outcome | 2006 |
The efficacy of cyclosporine A in cats with presumed atopic dermatitis: a double blind, randomised prednisolone-controlled study.
Topics: Animals; Blood Chemical Analysis; Cat Diseases; Cats; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Double-Blind Method; Female; Hematologic Tests; Male; Prednisolone; Pruritus; Severity of Illness Index; Treatment Outcome | 2009 |
Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cyclosporine; Dermatitis, Atopic; Female; Follow-Up Studies; Humans; Male; Middle Aged; Recurrence; Remission Induction; Time Factors | 1995 |
Maintenance treatment with cyclosporin in atopic eczema.
Topics: Adult; Chronic Disease; Cyclosporine; Dermatitis, Atopic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Remission Induction | 1994 |
Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study.
Topics: Adolescent; Adult; Aged; Cyclosporine; Dermatitis, Atopic; Double-Blind Method; Female; Humans; Male; Middle Aged; Severity of Illness Index | 1994 |
Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Cyclosporine; Dermatitis, Atopic; Double-Blind Method; Female; Humans; Male; Middle Aged; Quality of Life; Skin; Surveys and Questionnaires | 1993 |
Cyclosporine in severe childhood atopic dermatitis: a multicenter study.
Topics: Administration, Oral; Administration, Topical; Adolescent; Anti-Inflammatory Agents; Capsules; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Drug Tolerance; Female; Follow-Up Studies; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Quality of Life; Remission Induction; Safety; Solutions | 1996 |
Comparison of the steady state pharmacokinetics of two formulations of cyclosporin in patients with atopic dermatitis.
Topics: Adult; Chemistry, Pharmaceutical; Cross-Over Studies; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Emulsions; Female; Humans; Male; Middle Aged; Treatment Outcome | 1996 |
The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens.
Topics: Adolescent; Adult; Aged; Blood Pressure; Creatinine; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Pruritus; Sleep Wake Disorders; Treatment Outcome | 1996 |
Treatment of severe atopic dermatitis in childhood with cyclosporin.
Topics: Adolescent; Child; Child, Preschool; Creatinine; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Humans; Recurrence; Treatment Outcome | 1996 |
Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis.
Topics: Adolescent; Adult; Aged; Child; Cyclosporine; Dermatitis, Atopic; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Severity of Illness Index | 1997 |
Systemic cyclosporine A in severe atopic keratoconjunctivitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Conjunctivitis, Allergic; Cyclosporine; Dermatitis, Atopic; Female; Humans; Hypersensitivity; Immunosuppressive Agents; Keratitis; Kidney; Male; Middle Aged; Prednisone; Time Factors; Treatment Outcome | 1997 |
Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. Aa double-blind, single-centre, cross-over pilot study.
Topics: Adult; Cross-Over Studies; Cyclosporine; Dermatitis, Atopic; Double-Blind Method; Emulsions; Female; Headache; Humans; Immunosuppressive Agents; Male; Middle Aged; Nausea; Pilot Projects; Pruritus; Severity of Illness Index; Sleep Wake Disorders; Time Factors; Treatment Outcome | 1999 |
Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis: a possible new immune intervention.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Humans; Immunoglobulin E; Immunosuppressive Agents; Interleukin-4; Ki-1 Antigen; Th2 Cells; Treatment Outcome | 1999 |
Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy.
Topics: Adolescent; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Female; Humans; Male; Prospective Studies; Quality of Life; Recurrence; Treatment Outcome | 2000 |
A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life.
Topics: Adult; Body Weight; Cyclosporine; Dermatitis, Atopic; Dose-Response Relationship, Drug; Double-Blind Method; Emulsions; Female; Humans; Immunosuppressive Agents; Male; Prospective Studies; Quality of Life | 2000 |
Soluble CD30 and cyclosporine in severe atopic dermatitis.
Topics: Adolescent; Adult; Blood Proteins; Cyclosporine; Dermatitis, Atopic; Enzyme-Linked Immunosorbent Assay; Eosinophil Granule Proteins; Female; Humans; Immunoglobulin E; Immunosuppressive Agents; Ki-1 Antigen; Male; Middle Aged; Radioimmunoassay; Ribonucleases; Solubility; Treatment Outcome | 2000 |
[Cyclosporin in atopic dermatitis].
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Prospective Studies | 2001 |
Low-dose cyclosporin A microemulsion in children with severe atopic dermatitis: clinical and immunological effects.
Topics: Adolescent; Child; Cyclosporine; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Interleukin-13; Interleukin-4; Lymphocyte Subsets; Male; Severity of Illness Index | 2001 |
Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial.
Topics: Administration, Oral; Animals; California; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Double-Blind Method; Female; Male; North Carolina; Prednisolone; Prospective Studies; Pruritus; Severity of Illness Index; Treatment Outcome; Virginia | 2002 |
Cyclosporin maintenance therapy for severe atopic dermatitis.
Topics: Adult; Aged; Cyclosporine; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Severity of Illness Index | 1991 |
Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis.
Topics: Administration, Cutaneous; Cyclosporine; Dermatitis, Atopic; Dermatitis, Contact; Double-Blind Method; Drug Administration Schedule; Humans; Nickel; Ointments; Skin; Suspensions | 1991 |
Itch and atopic dermatitis: clinical and experimental studies.
Topics: Adolescent; Adult; Clemastine; Cyclosporine; Dermatitis, Atopic; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Male; Middle Aged; Pruritus; Terfenadine | 1991 |
182 other study(ies) available for cyclosporine and Dermatitis, Atopic
| Article | Year |
|---|---|
Effect of a combination of Korean red ginseng extract and probiotics on the prevention of atopic dermatitis in a murine model.
Topics: Animals; Biomarkers; Cyclosporine; Dermatitis, Atopic; Dinitrochlorobenzene; Gene Expression Regulation; Immunoglobulin E; Immunosuppressive Agents; Male; Mice; Panax; Phytotherapy; Plant Extracts; Probiotics; Random Allocation | 2022 |
Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD).
Topics: Adrenal Cortex Hormones; Adult; Cyclosporine; Dermatitis, Atopic; Humans; Methotrexate; Severity of Illness Index; Treatment Outcome | 2022 |
Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe.
Topics: Adolescent; Azathioprine; Biological Products; Child; Child, Preschool; Cyclosporine; Delphi Technique; Dermatitis, Atopic; Expert Testimony; Humans; Janus Kinase Inhibitors; Janus Kinases; Methotrexate; Mycophenolic Acid; Quality of Life | 2022 |
Real-world treatment patterns for atopic dermatitis in South Korea.
Topics: Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Glucocorticoids; Humans; Immunosuppressive Agents; Republic of Korea | 2022 |
European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy.
Topics: Adolescent; Azathioprine; Child; Cyclosporine; Dermatitis, Atopic; Eczema; Humans; Immunosuppressive Agents; Mycophenolic Acid | 2022 |
Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain.
Topics: Adrenal Cortex Hormones; Adult; Cyclosporine; Dermatitis, Atopic; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Spain | 2023 |
Annual Trends in Medicare Part D Prescription Claims for Dupilumab 2017 to 2019.
Topics: Aged; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatitis, Atopic; Humans; Medicare Part D; Methotrexate; Prescriptions; Severity of Illness Index; Treatment Outcome; United States | 2022 |
Systemic treatment for severe atopic dermatitis in children: a case series.
Topics: Azathioprine; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Humans; Methotrexate; Mycophenolic Acid; Prednisone; Thalidomide | 2022 |
Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain.
Topics: Adrenal Cortex Hormones; Adult; Cyclosporine; Dermatitis, Atopic; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Spain | 2023 |
Upadacitinib for moderate-to-severe atopic dermatitis, in adults and adolescents 12 years and older: review of international and Japanese populations.
Topics: Adolescent; Adult; Cyclosporine; Dermatitis, Atopic; Drug-Related Side Effects and Adverse Reactions; East Asian People; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Severity of Illness Index; Treatment Outcome | 2023 |
Long-term effects of ciclosporin and oclacitinib on mediators of tolerance, regulatory T-cells, IL-10 and TGF-β, in dogs with atopic dermatitis.
Topics: Animals; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Immune Tolerance; Interleukin-10; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2023 |
Cyclosporine induced generalized hyperkeratosis in a dog.
Topics: Animals; Chronic Disease; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Female; Hyperplasia; Immunosuppressive Agents; Papilloma | 2023 |
Differences in prescriptions for systemic medications and nonsteroidal topicals among children with atopic dermatitis.
Topics: Adolescent; Child; Cross-Sectional Studies; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Male; Prescriptions; Tacrolimus | 2023 |
BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings.
Topics: Administration, Cutaneous; Cyclosporine; Dermatitis, Atopic; Humans; Prospective Studies; Registries; Severity of Illness Index; Treatment Outcome | 2023 |
Three drugs for atopic dermatitis (Adbry, Cibinqo, and Rinvoq).
Topics: Cyclosporine; Dermatitis, Atopic; Double-Blind Method; Heterocyclic Compounds, 3-Ring; Humans; Severity of Illness Index; Treatment Outcome | 2023 |
Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitis.
Topics: Cyclosporine; Dermatitis, Atopic; Humans; Microbiota; RNA, Ribosomal, 16S; Severity of Illness Index; Skin; Staphylococcus aureus; Treatment Outcome | 2023 |
Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome: An Adverse Effect in a Patient With Atopic Dermatitis.
Topics: Cyclosporine; Dermatitis, Atopic; Drug-Related Side Effects and Adverse Reactions; Humans; Posterior Leukoencephalopathy Syndrome | 2023 |
[Algoritmo de tratamiento de la dermatitis atópica en Perú. Consenso de expertos].
Topics: Adult; Child; Cyclosporine; Dermatitis, Atopic; Humans; Peru; Quality of Life | 2023 |
A clinical trial in children and young people with severe eczema comparing methotrexate with ciclosporin.
Topics: Adolescent; Child; Cyclosporine; Dermatitis, Atopic; Eczema; Humans; Immunosuppressive Agents; Methotrexate | 2023 |
Atopic dermatitis in elderly adults.
Topics: Age Factors; Aged; Cohort Studies; Cyclosporine; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Geriatric Assessment; Hospitals, University; Humans; Immunoglobulin E; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Treatment Outcome | 2019 |
Topical nano-encapsulated cyclosporine formulation for atopic dermatitis treatment.
Topics: Administration, Topical; Animals; Cell Proliferation; Cyclosporine; Dermatitis, Atopic; Humans; Interleukin-2; Mice; Mice, Inbred BALB C; Nanoparticles; Organ Culture Techniques; Ovalbumin; Skin | 2020 |
Dermatologist attitudes toward ciclosporin use in atopic dermatitis.
Topics: Attitude; Cyclosporine; Dermatitis, Atopic; Dermatologists; Eczema; Humans | 2021 |
Drug survival and postdrug survival of systemic treatments in a national French cohort of children with atopic dermatitis.
Topics: Child; Cohort Studies; Cyclosporine; Dermatitis, Atopic; Eczema; Humans; Pharmaceutical Preparations | 2020 |
The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate-to-severe atopic eczema.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Europe; Humans; Phototherapy; Registries | 2020 |
Adverse event monitoring in patients on oral systemic medications for inflammatory skin disease.
Topics: Azathioprine; Cross-Sectional Studies; Cyclosporine; Dermatitis, Atopic; Drug Eruptions; Drug Monitoring; Humans; Methotrexate; Mycophenolic Acid; Psoriasis; United States | 2020 |
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.
Topics: Adult; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatitis, Atopic; Humans; Methotrexate; Pharmaceutical Preparations; Registries | 2020 |
[THREE CASES OF ATOPIC DERMATITIS CHILDREN WITH INTRACTABLE PRURIGO NODULARIS].
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Child; Cyclosporine; Dermatitis, Atopic; Female; Humans; Japan; Male; Prurigo; Quality of Life | 2020 |
Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatitis, Atopic; Humans; Pharmaceutical Preparations; Retrospective Studies; Treatment Outcome | 2020 |
Itch Relief in Atopic Dermatitis: Comparison of Narrowband Ultraviolet B Radiation and Cyclosporine Treatment.
Topics: Cyclosporine; Dermatitis, Atopic; Eczema; Humans; Pruritus; Ultraviolet Therapy | 2020 |
The prevalence of bacterial infections during cyclosporine therapy in dogs: A critically appraised topic.
Topics: Animals; Bacterial Infections; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Prevalence | 2020 |
Elevated NK-cell transcriptional signature and dysbalance of resting and activated NK cells in atopic dermatitis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Humans; Killer Cells, Natural; Skin; Transcriptome | 2021 |
Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Comorbidity; Cost of Illness; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Female; Humans; Male; Middle Aged; Prevalence; Prospective Studies; Quality of Life; Severity of Illness Index; Young Adult | 2021 |
Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Combined Modality Therapy; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Drug Resistance; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Methylprednisolone; Middle Aged; Retrospective Studies; Ultraviolet Therapy | 2021 |
Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae.
Topics: Antibodies, Monoclonal, Humanized; Conjunctivitis; Cyclosporine; Dermatitis, Atopic; Disease Progression; Eye Diseases; Humans; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2021 |
Novel agents for atopic dermatitis in patients over 50 years of age: A case series.
Topics: Aged; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatitis, Atopic; Eczema; Humans; Infant; Methotrexate; Treatment Outcome | 2021 |
Drug survival rates and reasons for drug discontinuation in patients with atopic dermatitis: a retrospective study of adult outpatients.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Azathioprine; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Female; Humans; Infant; Infant, Newborn; Kaplan-Meier Estimate; Male; Medication Adherence; Methotrexate; Middle Aged; Mycophenolic Acid; Outpatients; Patient Satisfaction; Probability; Proportional Hazards Models; Retrospective Studies; Young Adult | 2021 |
A single-centre real-life experience on effectiveness and safety of dupilumab in adolescents with severe atopic dermatitis in treatment with cyclosporine A.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatitis, Atopic; Humans; Injections, Subcutaneous; Severity of Illness Index; Treatment Outcome | 2021 |
[Epidemiology and treatment of adult patients with atopic dermatitis : Analysis of longitudinal data of the statutory health insurance scheme].
Topics: Adult; Calcineurin Inhibitors; Cyclosporine; Dermatitis, Atopic; Eczema; Humans; Insurance, Health | 2021 |
Low-Dose Cyclosporine A in the Treatment of Severe Atopic Dermatitis Complicated by Chronic Hepatitis C Virus Infection.
Topics: Adolescent; Cyclosporine; Dermatitis, Atopic; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Male; Tacrolimus | 2017 |
Decrease in serum IL-32 level in patients with atopic dermatitis after cyclosporine treatment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Enzyme-Linked Immunosorbent Assay; Humans; Interleukins; Male; Middle Aged; Treatment Outcome | 2017 |
A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents.
Topics: Animals; Cyclosporine; Cytokines; Dermatitis, Atopic; Female; Haptens; Humans; Immunoglobulin E; Inflammation; Interleukin-23; Interleukin-23 Subunit p19; Janus Kinase Inhibitors; Male; Methotrexate; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrroles; Rats; Rats, Inbred BN; Skin; Thymic Stromal Lymphopoietin | 2018 |
A Monocentric Retrospective Cohort of Patients with Severe Atopic Dermatitis Treated with Cyclosporine A in Daily Practice.
Topics: Adolescent; Adult; Cyclosporine; Dermatitis, Atopic; Drug Resistance; Female; France; Humans; Immunosuppressive Agents; Male; Remission Induction; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2017 |
[Keratoconjunctivitis associated with atopic dermatitis treated with tocilizumab].
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal, Humanized; Blindness; Cyclosporine; Dermatitis, Atopic; Female; Humans; Immunosuppressive Agents; Keratoconjunctivitis; Off-Label Use | 2018 |
Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Conjunctivitis; Cyclosporine; Dermatitis, Atopic; Freedom; Humans; Interleukin-17 | 2018 |
Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?: reply from the authors.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Conjunctivitis; Cyclosporine; Dermatitis, Atopic; Freedom; Humans; Interleukin-17 | 2018 |
[Current and upcoming treatments of adult atopic dermatitis].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Glucocorticoids; Humans; Methotrexate; Mycophenolic Acid; Piperidines; Pyrimidines; Pyrroles; Thalidomide; Ustekinumab | 2017 |
Drug survival and postdrug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine.
Topics: Adult; Alphavirus; Cyclosporine; Dermatitis, Atopic; Female; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Methotrexate; Proportional Hazards Models; Retrospective Studies; Time Factors; Young Adult | 2018 |
Use of oral immunosuppressive drugs in the treatment of atopic dermatitis in the Netherlands.
Topics: Administration, Oral; Azathioprine; Cyclosporine; Databases, Factual; Dermatitis, Atopic; Drug Prescriptions; Humans; Immunosuppressive Agents; Methotrexate; Mycophenolic Acid; Netherlands | 2018 |
Immediate Hypersensitivity Reactions Induced by Triamcinolone in a Patient with Atopic Dermatitis.
Topics: Adult; Anti-Inflammatory Agents; Cyclosporine; Dermatitis, Atopic; Dexamethasone; Drug Hypersensitivity; Epinephrine; Female; Glucocorticoids; Histamine Antagonists; Humans; Skin Tests; Triamcinolone | 2018 |
After the approval of dupilumab for moderate-to-severe atopic dermatitis: what is next on the research agenda?
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatitis, Atopic; Freedom; Humans | 2018 |
An embarrassment of riches: An update on the symptomatic treatment of canine atopic dermatitis.
Topics: Animals; Antibodies, Monoclonal; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Glucocorticoids; Pyrimidines; Sulfonamides | 2018 |
Generating new evidence for old medications: the TREAT trial in paediatric atopic dermatitis.
Topics: Child; Cost-Benefit Analysis; Cyclosporine; Dermatitis, Atopic; Eczema; Humans; Methotrexate | 2018 |
Dupilumab-Induced Follicular Conjunctivitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Conjunctivitis; Cyclosporine; Dermatitis, Atopic; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Interleukin-4 Receptor alpha Subunit; Male; Olopatadine Hydrochloride; Prednisolone; Slit Lamp Microscopy | 2019 |
EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with cyclosporin A.
Topics: Cyclosporine; Dermatitis, Atopic; Disease Management; Humans; Immunosuppressive Agents; Prognosis; Severity of Illness Index; Treatment Outcome | 2019 |
Cyclosporine-A for severe childhood atopic dermatitis: clinical experience on efficacy \
and safety profile
Topics: Adolescent; Child; Cyclosporine; Dermatitis, Atopic; Female; Humans; Male; Retrospective Studies; Treatment Outcome | 2018 |
High incidence of acquiring methicillin-resistant Staphylococcus aureus in Brazilian children with Atopic Dermatitis and associated risk factors.
Topics: Adolescent; Anti-Bacterial Agents; Brazil; Child; Child, Preschool; Cohort Studies; Cyclosporine; Dermatitis, Atopic; Female; Histamine Antagonists; Humans; Incidence; Infant; Male; Methicillin-Resistant Staphylococcus aureus; Multivariate Analysis; Prospective Studies; Protective Factors; Risk Factors; Staphylococcal Infections | 2020 |
Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
Topics: Adult; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Remission Induction; Severity of Illness Index; Skin; Time Factors; Treatment Outcome; Young Adult | 2019 |
Cyclosporine 0.1% (Ikervis
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal, Humanized; Conjunctivitis; Cyclosporine; Dermatitis, Atopic; Female; Fluorometholone; Glucocorticoids; Humans; Immunosuppressive Agents; Interleukin-4 Receptor alpha Subunit; Male; Middle Aged; Recurrence | 2019 |
Health-care resource use and current treatment of adult atopic dermatitis patients in Japan: A retrospective claims database analysis.
Topics: Adult; Ambulatory Care; Cost of Illness; Cyclosporine; Databases, Factual; Dermatitis, Atopic; Dermatologic Agents; Drug Prescriptions; Female; Glucocorticoids; Hospitalization; Humans; Japan; Male; Middle Aged; Patient Acceptance of Health Care; Phototherapy; Retrospective Studies; Young Adult | 2019 |
Cutaneous nocardiosis in two dogs receiving ciclosporin therapy for the management of canine atopic dermatitis.
Topics: Animals; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Female; Immunosuppression Therapy; Immunosuppressive Agents; Male; Nocardia Infections | 2013 |
Systemic therapies for severe atopic dermatitis in children and adults.
Topics: Adult; Azathioprine; Child; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Male; Methotrexate; Quality of Life | 2013 |
Neurotoxicity in the setting of pediatric atopic dermatitis treated with modified cyclosporine and itraconazole.
Topics: Adolescent; Cyclosporine; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Itraconazole; Male; Neurotoxicity Syndromes; Risk Assessment | 2013 |
Kaposi sarcoma in an patient with atopic dermatitis treated with ciclosporin.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Leg; Male; Sarcoma, Kaposi; Skin; Skin Neoplasms | 2013 |
Methotrexate vs. ciclosporin in the treatment of severe atopic dermatitis in children: a critical appraisal.
Topics: Cyclosporine; Dermatitis, Atopic; Female; Humans; Immunosuppressive Agents; Male; Methotrexate | 2014 |
Commentary: Methotrexate and ciclosporin in the treatment of severe eczema in children.
Topics: Cyclosporine; Dermatitis, Atopic; Female; Humans; Immunosuppressive Agents; Male; Methotrexate | 2014 |
Ciclosporin in canine dermatology: a decade of comfort.
Topics: Animals; Combined Modality Therapy; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Veterinary Medicine | 2014 |
Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology.
Topics: Adolescent; Adult; Aged; Biomarkers; Cluster Analysis; Cyclosporine; Dendritic Cells; Dermatitis, Atopic; Epidermis; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Hyperplasia; Immunosuppressive Agents; Inflammation; Male; Middle Aged; Phenotype; Signal Transduction; T-Lymphocyte Subsets; Treatment Outcome; Young Adult | 2014 |
Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents.
Topics: Anti-Infective Agents; Azathioprine; Cyclosporine; Dermatitis, Atopic; Histamine Antagonists; Humans; Immunologic Factors; Interferon-gamma; Methotrexate; Mycophenolic Acid; Phototherapy | 2014 |
Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence.
Topics: Biomarkers, Pharmacological; Cells, Cultured; Claudins; Clinical Protocols; Cyclosporine; Dermatitis, Atopic; Follow-Up Studies; Genome; Humans; Immunosuppressive Agents; Interferon-gamma; Leptin; Recurrence; T-Lymphocyte Subsets; Th2 Cells; Transcriptome; Treatment Outcome; Ultraviolet Therapy | 2014 |
Consensus on the use of cyclosporine in dermatological practice. Italian Consensus Conference.
Topics: Adult; Child; Cyclosporine; Dermatitis, Atopic; Disease Susceptibility; Drug Administration Schedule; Drug Interactions; Female; Food-Drug Interactions; Humans; Hypertension; Immunosuppressive Agents; Infections; Kidney Diseases; Neoplasms; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Psoriasis; Quality of Life; Skin Diseases | 2014 |
Different effect of oral cyclosporine therapy and oral antihistamine therapy on serum high-sensitivity C-reactive protein level and thymus and activation-regulated chemokine level in atopic dermatitis in older children and adulthood.
Topics: Administration, Oral; Adolescent; Adult; C-Reactive Protein; Chemokine CCL17; Cyclosporine; Dermatitis, Atopic; Female; Histamine Antagonists; Humans; Male; Treatment Outcome; Young Adult | 2015 |
Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis.
Topics: Adult; Age Factors; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Drug Administration Schedule; Drug Substitution; Female; Humans; Long-Term Care; Male; Retrospective Studies; Treatment Outcome | 2015 |
Vernal Keratoconjunctivitis and immune-mediated diseases: One unique way to symptom control?
Topics: Adolescent; Asthma; Conjunctivitis, Allergic; Cyclosporine; Dermatitis, Atopic; Disease Progression; Humans; Immunoglobulin E; Male; Omalizumab; Th1 Cells; Th2 Cells | 2015 |
Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres.
Topics: Academic Medical Centers; Administration, Oral; Adult; Azathioprine; Cyclosporine; Dermatitis, Atopic; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Tacrolimus; Young Adult | 2015 |
Cyclosporine in psoriasis: comparison of a 25-year real-world Italian experience to current European guidelines.
Topics: Adult; Child; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Europe; Humans; Immunosuppressive Agents; Italy; Practice Guidelines as Topic; Psoriasis | 2016 |
Serum creatinine levels during and after long-term treatment with cyclosporine A in patients with severe atopic dermatitis.
Topics: Adult; Age Factors; Creatinine; Cyclosporine; Dermatitis, Atopic; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kidney; Maintenance Chemotherapy; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Time Factors; Young Adult | 2015 |
[Prosthetic Valve Endocarditis using Immunosuppressive Agent for Atopic Dermatitis;Report of a Case].
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Endocarditis, Bacterial; Heart Valve Prosthesis; Humans; Immunosuppressive Agents; Intracranial Embolism; Male; Staphylococcal Infections; Tomography, X-Ray Computed | 2015 |
Long-term use of ciclosporin in a real-world setting.
Topics: Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Female; Humans; Male | 2015 |
DIAGNOSIS AND PALLIATIVE MANAGEMENT OF ATOPIC DERMATITIS IN A MALAYAN FLYING FOX (PTEROPUS VAMPYRUS).
Topics: Animals; Chiroptera; Cyclosporine; Dermatitis, Atopic; Glucocorticoids; Immunosuppressive Agents; Male; Triamcinolone | 2015 |
Cyclosporine A microemulsion in dermatological practice: is oral solution better tolerated than soft gelatin capsules?
Topics: Administration, Oral; Adolescent; Adult; Aged; Capsules; Cyclosporine; Dermatitis, Atopic; Dermatitis, Contact; Emulsions; Female; Gelatin; Humans; Immunosuppressive Agents; Middle Aged; Pharmaceutical Solutions; Psoriasis | 2015 |
IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long-term systemic cyclosporine A treatment.
Topics: Adult; Allergens; Autoantigens; Cyclosporine; Dermatitis, Atopic; Female; Humans; Immunoglobulin E; Immunosuppressive Agents; Male; Middle Aged; Time Factors; Treatment Outcome | 2016 |
The anti-IL-4 receptor alpha antibody dupilumab: facing a new era in treating atopic dermatitis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Clinical Trials as Topic; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Methotrexate; Quality of Life; Receptors, Interleukin-4; Treatment Outcome | 2015 |
First experience with extended release tacrolimus in the treatment of adult patients with severe, difficult to treat atopic dermatitis: Clinical efficacy, safety and dose finding.
Topics: Adolescent; Adult; Aged; Calcineurin Inhibitors; Cyclosporine; Delayed-Action Preparations; Dermatitis, Atopic; Drug Evaluation; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Tacrolimus; Treatment Outcome; Young Adult | 2016 |
Lymphocyte subpopulations and Treg cells in dogs with atopic dermatitis receiving ciclosporin therapy: a prospective study.
Topics: Animals; Anti-Infective Agents; Case-Control Studies; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Female; Immunosuppressive Agents; Male; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory | 2016 |
Possible Antipruritic Mechanism of Cyclosporine A in Atopic Dermatitis.
Topics: Administration, Topical; Animals; Antipruritics; Behavior, Animal; Cyclosporine; Dermatitis, Atopic; Dermatophagoides farinae; Disease Models, Animal; Immunosuppressive Agents; Male; Mice; Mice, Inbred Strains; Pruritus; Reverse Transcriptase Polymerase Chain Reaction | 2016 |
Long-term Use of Systemic Treatments for Moderate-to-Severe Atopic Dermatitis in Adults: A Monocentric Retrospective Study.
Topics: Adolescent; Adult; Aged; Azathioprine; Cyclosporine; Dermatitis, Atopic; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Retrospective Studies; Treatment Outcome | 2016 |
Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis.
Topics: Adult; Antibiotics, Antineoplastic; Cyclosporine; Dermatitis, Atopic; Female; Genotype; Glucuronosyltransferase; Humans; Immunosuppressive Agents; Logistic Models; Male; Middle Aged; Mycophenolic Acid; Odds Ratio; Polymorphism, Single Nucleotide; Precision Medicine; Retrospective Studies; Severity of Illness Index; UDP-Glucuronosyltransferase 1A9 | 2017 |
An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease.
Topics: Adolescent; Adult; Aged; Biomarkers; Chemokine CCL17; Cohort Studies; Cyclosporine; Dermatitis, Atopic; Epidermis; Female; Humans; Interleukin-13; Interleukin-22; Interleukins; Keratin-16; Male; Middle Aged; Multivariate Analysis; Th2 Cells; Young Adult | 2017 |
Editorial on Guidelines for the Management of Atopic Dermatitis in Singapore.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Azathioprine; Calcineurin Inhibitors; Cyclosporine; Dermatitis, Atopic; Disease Management; Food Hypersensitivity; Humans; Immunosuppressive Agents; Patient Education as Topic; Phototherapy; Practice Guidelines as Topic; Severity of Illness Index; Singapore | 2016 |
Hospital-diagnosed atopic dermatitis and long-term risk of myocardial infarction: a population-based follow-up study.
Topics: Adult; Aged; Ambulatory Care; Azathioprine; Case-Control Studies; Cyclosporine; Denmark; Dermatitis, Atopic; Eczema; Female; Follow-Up Studies; Hospitalization; Hospitals; Humans; Immunosuppressive Agents; Incidence; Male; Methotrexate; Middle Aged; Myocardial Infarction; Registries; Risk Factors; Young Adult | 2016 |
Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey.
Topics: Adult; Azathioprine; Canada; Child; Cyclosporine; Dermatitis, Atopic; Dermatology; Drug Prescriptions; Female; Health Care Surveys; Humans; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Pediatrics; Practice Patterns, Physicians'; Severity of Illness Index; United States | 2017 |
Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany.
Topics: Adult; Alitretinoin; Anti-Inflammatory Agents; Azathioprine; Cyclosporine; Dermatitis, Atopic; Female; Follow-Up Studies; Humans; Leflunomide; Long-Term Care; Male; Methotrexate; Mycophenolic Acid; Prednisolone; Registries; Treatment Outcome | 2017 |
Cyclosporine A for severe atopic dermatitis in children. efficacy and safety in a retrospective study of 63 patients.
Topics: Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Female; Humans; Male; Retrospective Studies | 2017 |
Cyclosporine use in miscellaneous clinical settings other than organ transplantations: is there any evidence for target levels?
Topics: Adolescent; Adult; Autoimmune Diseases; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Dermatomyositis; Female; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Monitoring, Physiologic; Purpura, Thrombocytopenic, Idiopathic; Transplantation Immunology; Young Adult | 2008 |
Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forkhead Transcription Factors; Humans; Immunosuppressive Agents; Lymphocyte Activation; Male; Middle Aged; T-Lymphocytes, Regulatory; Treatment Outcome; Young Adult | 2009 |
Topical administration of cyclosporin A in a solid lipid nanoparticle formulation.
Topics: Administration, Topical; Animals; Cells, Cultured; Chemistry, Pharmaceutical; Cyclosporine; Dermatitis, Atopic; Electrochemistry; Female; Immunosuppressive Agents; In Vitro Techniques; Liposomes; Mice; Mice, Hairless; Nanoparticles; Particle Size; Skin Absorption | 2009 |
Cyclosporin A reduces CD4(+)CD25(+) regulatory T-cell numbers in patients with atopic dermatitis.
Topics: Adult; CD4 Lymphocyte Count; Cyclosporine; Dermatitis, Atopic; Female; Forkhead Transcription Factors; Humans; Immunosuppressive Agents; Male; Middle Aged; T-Lymphocytes, Regulatory | 2009 |
Severe atopic dermatitis treated with everolimus.
Topics: Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Drug Therapy, Combination; Everolimus; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Middle Aged; Severity of Illness Index; Sirolimus; Treatment Failure | 2009 |
A case of atopic dermatitis-associated lichen amyloidosis successfully treated with oral cyclosporine and narrow band UVB therapy in succession.
Topics: Administration, Oral; Adult; Amyloidosis; Combined Modality Therapy; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Female; Humans; Lichen Planus; Treatment Outcome; Ultraviolet Therapy | 2009 |
Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Baths; Chronic Disease; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Glucocorticoids; Tacrolimus | 2010 |
Low-dose, but not high-dose, cyclosporin A promotes regulatory T-cell induction, expansion, or both.
Topics: Cyclosporine; Dermatitis, Atopic; Dose-Response Relationship, Drug; Humans; Immunosuppressive Agents; Interleukin-2; T-Lymphocytes, Regulatory | 2010 |
Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis.
Topics: Animals; Antipruritics; Behavior, Animal; Calcineurin Inhibitors; Capillary Permeability; Cyclosporine; Dermatitis, Atopic; Dinitrofluorobenzene; Disease Models, Animal; Immunosuppressive Agents; Male; Mice; Mice, Inbred BALB C; Passive Cutaneous Anaphylaxis; Pruritus; Tacrolimus | 2010 |
Bone mineral density in children with moderate to severe atopic dermatitis.
Topics: Absorptiometry, Photon; Adolescent; Adrenal Cortex Hormones; Bone Density; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Female; Fractures, Bone; Humans; Immunosuppressive Agents; Lumbar Vertebrae; Male; Osteoporosis; Prevalence; Risk Factors; Severity of Illness Index; Tacrolimus | 2010 |
Presumptive Nocardia spp. infection in a dog treated with cyclosporin and ketoconazole.
Topics: Animals; Antifungal Agents; Cyclosporine; Dermatitis, Atopic; Dogs; Female; Immunosuppression Therapy; Immunosuppressive Agents; Ketoconazole; Nocardia; Nocardia Infections; Opportunistic Infections | 2010 |
Favorable clinical response by pre-prandial administration of low-dose ciclosporin to severe adult atopic dermatitis.
Topics: Adult; Area Under Curve; Cyclosporine; Dermatitis, Atopic; Drug Monitoring; Female; Humans; Immunosuppressive Agents; Male; Time Factors | 2012 |
[Health services research the example of atopic dermatitis].
Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Comorbidity; Cross-Sectional Studies; Cyclosporine; Delphi Technique; Dermatitis, Atopic; Dermatologic Agents; Evidence-Based Medicine; Germany; Health Services Research; Humans; National Health Programs; Neurodermatitis; Practice Patterns, Physicians'; Prednisolone; Quality Assurance, Health Care; Translational Research, Biomedical; Treatment Outcome | 2011 |
The evaluation of Canine Atopic Dermatitis Extent and Severity Index (CADESI) test in dogs with atopic dermatitis (AD) treated with cyclosporine or prednisone.
Topics: Animals; Cyclosporine; Dermatitis, Atopic; Dog Diseases; Dogs; Female; Immunosuppressive Agents; Male; Prednisone | 2010 |
Evaluation of a human generic formulation of ciclosporin in the treatment of canine atopic dermatitis with in vitro assessment of the functional capacity of phagocytic cells.
Topics: Animals; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Female; Humans; Male; Phagocytes; Pilot Projects; Prednisone; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2011 |
Tapering cyclosporine after long-term treatment of atopic dermatitis.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Female; Humans; Immunosuppressive Agents; Male; Middle Aged | 2012 |
Atopic dermatitis-like pre-Sézary syndrome: role of immunosuppression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclosporine; Dermatitis, Atopic; Diagnostic Errors; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Precancerous Conditions; Predictive Value of Tests; Sezary Syndrome; Skin; Skin Neoplasms; Treatment Outcome | 2011 |
Prednisolone is associated with an increase in serum insulin but not serum fructosamine concentrations in dogs with atopic dermatitis.
Topics: Animals; Anti-Inflammatory Agents; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Female; Fructosamine; Insulin; Male; Prednisolone; Treatment Outcome | 2012 |
Primary localized cutaneous nodular amyloidosis that appeared in a patient with severe atopic dermatitis.
Topics: Adult; Amyloidosis; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Male; Skin Diseases | 2012 |
[Treatment-resistant adult atopic dermatitis].
Topics: Adrenal Cortex Hormones; Adult; Cyclosporine; Dermatitis, Allergic Contact; Dermatitis, Atopic; Dermatitis, Occupational; Dietary Proteins; Drug Resistance; Facial Dermatoses; Female; Food Hypersensitivity; Hand Dermatoses; Histamine Antagonists; Humans; Immunosuppressive Agents; Methotrexate; Patch Tests; Skin Tests; Tacrolimus | 2011 |
[Eccema herpeticum].
Topics: Acyclovir; Adrenal Cortex Hormones; Adult; Antiviral Agents; Cyclosporine; Dermatitis, Atopic; Eczema; Herpes Simplex; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; PUVA Therapy; Simplexvirus; Virus Activation | 2012 |
Treatment of severe refractory adult atopic dermatitis with ustekinumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatitis, Atopic; Eczema; Female; Humans; Immunosuppressive Agents; Prednisone; Pruritus; Severity of Illness Index; Ultraviolet Therapy; Ustekinumab; Young Adult | 2012 |
Factors determining the effectiveness of oral ciclosporin in the treatment of severe childhood atopic dermatitis.
Topics: Adolescent; Anti-Bacterial Agents; Child; Cyclosporine; Dermatitis, Atopic; Female; Humans; Immunosuppressive Agents; Male; Retrospective Studies; Severity of Illness Index; Staphylococcal Skin Infections; Staphylococcus aureus | 2012 |
Let's not presuppose that patients take their medications.
Topics: Cyclosporine; Dermatitis, Atopic; Female; Humans; Immunosuppressive Agents; Male; Staphylococcal Skin Infections; Staphylococcus aureus | 2012 |
Mechanism underlying the effect of combined therapy using glucosamine and low-dose cyclosporine A on the development of atopic dermatitis-like skin lesions in NC/Nga mice.
Topics: Animals; Antigens, Dermatophagoides; CD4 Antigens; Cells, Cultured; Cyclosporine; Cytokines; Dermatitis, Atopic; Dermatophagoides farinae; Drug Dosage Calculations; Drug Therapy, Combination; Eosinophils; Filaggrin Proteins; Glucosamine; Humans; Immunoglobulin E; Immunosuppressive Agents; Interleukin-2 Receptor alpha Subunit; Intermediate Filament Proteins; Keratins; Male; Mast Cells; Mice; Mice, Inbred Strains; Skin; T-Lymphocytes, Regulatory; Th1-Th2 Balance | 2013 |
Atopic dermatitis-like presentation of graft-versus-host disease: a novel form of chronic cutaneous graft-versus-host disease.
Topics: Adolescent; Adult; Chronic Disease; Cyclosporine; Dermatitis, Atopic; Diagnosis, Differential; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Skin; Skin Diseases; T-Lymphocytes; Young Adult | 2013 |
Eczema herpeticum with herpetic folliculitis after bone marrow transplant under prophylactic acyclovir: are patients with underlying dermatologic disorders at higher risk?
Topics: Acyclovir; Adult; Anemia, Aplastic; Antiviral Agents; Bone Marrow Transplantation; Cyclosporine; Dermatitis, Atopic; Female; Folliculitis; Herpes Simplex; Herpesvirus 1, Human; Humans; Kaposi Varicelliform Eruption; Risk Factors | 2013 |
Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Humans; Lymphoma, T-Cell, Cutaneous; Male; Skin Neoplasms | 2002 |
Refractory atopic dermatitis treated with low dose cyclosporin.
Topics: Cyclosporine; Dermatitis, Atopic; Diagnosis, Differential; Humans; Immunosuppressive Agents; Male; Middle Aged; Treatment Outcome | 2002 |
Cyclosporin A and alopecia areata.
Topics: Adult; Alopecia Areata; Cyclosporine; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Male; Severity of Illness Index; Treatment Outcome | 2002 |
Cyclosporin in the treatment of severe atopic dermatitis: a retrospective study.
Topics: Adolescent; Adult; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Infant; Male; Middle Aged; Retrospective Studies | 2004 |
Enhanced TARC production by dust-mite allergens and its modulation by immunosuppressive drugs in PBMCs from patients with atopic dermatitis.
Topics: Adult; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemokine CCL17; Chemokines, CC; Cyclosporine; Dendritic Cells; Dermatitis, Atopic; Dexamethasone; Dust; Female; Humans; Immunosuppressive Agents; Leukocytes, Mononuclear; Male; NF-kappa B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tacrolimus; Up-Regulation | 2004 |
An economic evaluation of intermittent cyclosporin A therapy versus UVAB phototherapy in the treatment of patients with severe atopic dermatitis.
Topics: Adult; Aged; Confidence Intervals; Cost of Illness; Cost Savings; Cost-Benefit Analysis; Cyclosporine; Delivery of Health Care; Dermatitis, Atopic; Female; Finland; Health Care Costs; Humans; Male; Middle Aged; Probability; Risk Assessment; Severity of Illness Index; Treatment Outcome; Ultraviolet Therapy; United States | 2004 |
A case of fatal systemic toxoplasmosis in a cat being treated with cyclosporin A for feline atopy.
Topics: Animals; Cat Diseases; Cats; Cyclosporine; Dermatitis, Atopic; Diagnosis, Differential; Fatal Outcome; Immunocompromised Host; Male; Parasitemia; Toxoplasmosis, Animal | 2004 |
Cyclosporin is safe and effective in severe atopic dermatitis of childhood. Report of three cases.
Topics: Child, Preschool; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Male | 2004 |
Non-Hodgkin's lymphoma following treatment of atopic eczema with cyclosporin A.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosphamide; Cyclosporine; Dermatitis, Atopic; Disease Progression; Doxorubicin; Fatal Outcome; Female; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Staging; Prednisolone; Severity of Illness Index; Vincristine | 2004 |
Cyclosporine treatment decreases the percentage of cutaneous lymphocyte antigen (CLA)(+)CD4(+) T cells in children with severe atopic dermatitis.
Topics: Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; CD4-Positive T-Lymphocytes; Child; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Membrane Glycoproteins | 2004 |
Long-term use of cyclosporine in the treatment of canine atopic dermatitis.
Topics: Animals; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Drug Administration Schedule; Female; Male; Pruritus; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2005 |
Successful cyclosporine treatment for atopic dermatitis in a rhesus macaque (Macaca mulatta).
Topics: Administration, Oral; Animals; Biopsy; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Female; Immunosuppressive Agents; Macaca mulatta; Monkey Diseases; Treatment Outcome | 2005 |
Myotoxicity occurring with ciclosporin in a patient with atopic dermatitis.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Male; Muscular Diseases | 2005 |
Dermal microdialysis in the dog: in vivo assessment of the effect of cyclosporin A on cutaneous histamine and prostaglandin D2 release.
Topics: Administration, Oral; Animals; Ascaris suum; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Female; Histamine; Histamine Release; Immunosuppressive Agents; Microdialysis; Prostaglandin D2; Time Factors | 2006 |
Macrophage-derived chemokine (MDC)/CCL22 produced by monocyte derived dendritic cells reflects the disease activity in patients with atopic dermatitis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Chemokine CCL17; Chemokine CCL22; Chemokines, CC; Cyclosporine; Dendritic Cells; Dermatitis, Atopic; Dermatologic Agents; Dexamethasone; Female; Gene Expression Regulation; Humans; Immunosuppressive Agents; Interleukin-12; Interleukin-18; Male; Middle Aged; Monocytes; Psoriasis; Severity of Illness Index; Tacrolimus | 2006 |
Aggressive CD30 large cell lymphoma after cyclosporine given for putative atopic dermatitis.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Ki-1 Antigen; Lymphoma, T-Cell, Cutaneous; Male; Skin Neoplasms | 2006 |
Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis.
Topics: Adult; Creatine; Cyclosporine; Dermatitis, Atopic; Female; Humans; Kidney; Male; Remission Induction; Retrospective Studies; Treatment Outcome | 2007 |
Effects of cyclosporin A and cilomilast on activated canine, murine and human keratinocytes.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Carboxylic Acids; Cell Proliferation; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclosporine; Dermatitis, Atopic; Dinoprostone; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Keratinocytes; Mice; Nitriles; Phosphodiesterase Inhibitors; Species Specificity | 2007 |
Cyclosporin A treatment is associated with increased serum immunoglobulin E levels in a subgroup of atopic dermatitis patients.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Diagnosis, Differential; Eczema; Humans; Immunoglobulin E; Immunosuppressive Agents | 2007 |
Postkeratoplasty atopic sclerokeratitis in keratoconus patients.
Topics: Adult; Betamethasone; Blepharitis; Corneal Neovascularization; Cyclosporine; Dermatitis, Atopic; Female; Humans; Hypersensitivity, Immediate; Immunosuppressive Agents; Incidence; Keratitis; Keratoconus; Keratoplasty, Penetrating; Male; Ophthalmic Solutions; Postoperative Complications; Retrospective Studies; Risk Factors; Scleritis; Time Factors; Visual Acuity | 2008 |
Combination of low-dosage cyclosporine and topical pimecrolimus in severe atopic dermatitis with chronic hepatitis B.
Topics: Calcineurin Inhibitors; Cyclosporine; Dermatitis, Atopic; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Middle Aged; Skin; Tacrolimus | 2008 |
Permanent remission of severe atopic dermatitis in a Chinese patient after cyclosporin A therapy.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Humans; Male; Remission Induction | 1995 |
Reduced cytokine production in response to stimulation with dust mite antigen after cyclosporin A treatment of atopic dermatitis.
Topics: Adult; Antigens, Dermatophagoides; Cells, Cultured; Cyclosporine; Cytokines; Depression, Chemical; Dermatitis, Atopic; Glycoproteins; Humans; Leukocytes, Mononuclear; Male; Th1 Cells | 1995 |
Cyclosporin A in severe, therapy-resistant atopic dermatitis: report of an international workshop, April 1993.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Double-Blind Method; Drug Interactions; Drug Monitoring; Guidelines as Topic; Humans; Patient Selection; Placebos; Psoriasis; Randomized Controlled Trials as Topic; Safety | 1993 |
An unexpected increase in circulating IFN-gamma by cyclosporin A in atopic patients: a discrepancy between in vitro and in vivo events.
Topics: Administration, Oral; Adult; Cyclosporine; Dermatitis, Atopic; Humans; Interferon-gamma; Interleukin-1; Male; Middle Aged; Severity of Illness Index; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 1994 |
Cyclosporin A treatment of severe atopic dermatitis in a child.
Topics: Cyclosporine; Dermatitis, Atopic; Humans; Infant | 1994 |
Spontaneous expression of IL-4 mRNA in lymphocytes from children with atopic dermatitis.
Topics: Base Sequence; beta 2-Microglobulin; Cells, Cultured; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; DNA Primers; Gene Expression; Humans; Immunoglobulin E; Infant; Interleukin-4; Lymphocyte Activation; Molecular Sequence Data; Polymerase Chain Reaction; RNA, Messenger; T-Lymphocytes | 1994 |
Production and secretion of interferon-gamma (IFN-gamma) in children with atopic dermatitis.
Topics: Adolescent; Cells, Cultured; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Humans; Infant; Infant, Newborn; Interferon-gamma; Leukocytes, Mononuclear; Tetradecanoylphorbol Acetate | 1994 |
Can cyclosporin A induce permanent remission of atopic dermatitis?
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Dose-Response Relationship, Drug; Female; Humans; Long-Term Care; Male; Middle Aged; Time Factors | 1993 |
Production of interleukin-5 and the suppressive effect of cyclosporin A in childhood severe atopic dermatitis.
Topics: Child, Preschool; Cyclosporine; Cytokines; Dermatitis, Atopic; Humans; Interleukin-5; Male | 1996 |
Long-term use of cyclosporine in dermatology.
Topics: Cyclosporine; Dermatitis, Atopic; Humans; Psoriasis; Time Factors | 1996 |
A new microemulsion formulation of cyclosporin (Neoral) is effective in the treatment of cyclosporin-resistant dermatoses.
Topics: Adult; Chemistry, Pharmaceutical; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Drug Resistance; Emulsions; Humans; Male; Middle Aged; Psoriasis | 1996 |
Effects of dexamethasone and cyclosporin A on the accumulation of eosinophils in acute cutaneous inflammation in the guinea-pig.
Topics: Animals; Cycloheximide; Cyclosporine; Dermatitis, Atopic; Dexamethasone; Edema; Eosinophils; Guinea Pigs; Immunosuppressive Agents | 1996 |
Modulation of serum eosinophil cationic protein levels by cyclosporin in severe atopic dermatitis.
Topics: Adolescent; Adult; Aged; Cyclosporine; Dermatitis, Atopic; Eosinophils; Humans; Immunosuppressive Agents; Middle Aged | 1996 |
[Treatment of atopic dermatitis].
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Age Factors; Child; Cyclosporine; Dermatitis, Atopic; Histamine Antagonists; Humans; Hypertension; Kidney; PUVA Therapy | 1997 |
Cyclosporine in children with severe atopic dermatitis.
Topics: Child; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents | 1997 |
Cyclosporine restores cytokine imbalance in childhood atopic dermatitis.
Topics: Cells, Cultured; Child; Cyclosporine; Dermatitis, Atopic; Humans; Immunoglobulin E; Interferon-gamma; Interleukin-4; Male; Th1 Cells; Th2 Cells | 1997 |
Long-term follow-up of eczema patients treated with cyclosporine.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Dermatitis, Contact; Eczema; Female; Follow-Up Studies; Hand; Humans; Immunosuppressive Agents; Male; Photosensitivity Disorders | 1998 |
[Atopic dermatitis].
Topics: Administration, Topical; Adolescent; Adult; Age Factors; Allergens; Anti-Inflammatory Agents; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Drugs, Chinese Herbal; Emollients; Fatty Acid Desaturases; Food Hypersensitivity; gamma-Linolenic Acid; Glucocorticoids; Humans; Immunoglobulin E; Immunosuppressive Agents; Infant; Infant, Newborn; Irritants; Linoleoyl-CoA Desaturase; Metabolism, Inborn Errors; Prevalence; PUVA Therapy; Skin; Th2 Cells; Ultraviolet Therapy | 1998 |
Morphological assessment of the effects of cyclosporin A on mast cell--nerve relationship in atopic dermatitis.
Topics: Adult; Cell Count; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Male; Mast Cells; Nerve Fibers; Nervous System; Skin | 1998 |
Fever associated with cyclosporin for treating atopic dermatitis.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Female; Fever; Humans | 1998 |
The efficacy, tolerability and safety of a new oral formulation of Sandimmun--Sandimmun Neoral in severe refractory atopic dermatitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Male; Middle Aged | 1998 |
Soluble E-selectin correlates with disease activity in cyclosporin A-treated patients with atopic dermatitis.
Topics: Adult; Aged; Biomarkers; Cyclosporine; Dermatitis, Atopic; E-Selectin; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Solubility | 1999 |
Overexpression of CD11b on eosinophils in atopic dermatitis: downregulation by cyclosporin A and upregulation by interleukin 5.
Topics: Cyclosporine; Dermatitis, Atopic; Down-Regulation; Eosinophils; Flow Cytometry; Humans; Immunosuppressive Agents; Interleukin-5; Macrophage-1 Antigen; Up-Regulation | 1999 |
Penetrating keratoplasty in patients with atopic dermatitis with and without systemic cyclosporin A.
Topics: Adolescent; Adult; Aged; Child; Corneal Diseases; Cyclosporine; Dermatitis, Atopic; Graft Survival; Humans; Immunosuppressive Agents; Keratitis; Keratoconus; Keratoplasty, Penetrating; Middle Aged; Postoperative Care; Prognosis; Retrospective Studies | 1999 |
[Immunosuppressive macrolides and their use in dermatology].
Topics: Administration, Topical; Clinical Trials as Topic; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Psoriasis; Sirolimus; Tacrolimus | 2000 |
A rapid flow cytometric assay to detect CD4+ and CD8+ T-helper (Th) 0, Th1 and Th2 cells in whole blood and its application to study cytokine levels in atopic dermatitis before and after cyclosporin therapy.
Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclosporine; Cytokines; Dermatitis, Atopic; Dermatologic Agents; Eosinophils; Female; Flow Cytometry; Humans; Immunosuppressive Agents; Leukocyte Count; Male; Middle Aged; T-Lymphocyte Subsets; T-Lymphocytes, Helper-Inducer; Th1 Cells; Th2 Cells | 2001 |
Skin disease. Eczema.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Child; Cyclosporine; Dermatitis, Atopic; Glucocorticoids; Humans; Immunosuppressive Agents; Tacrolimus | 2001 |
Lichen amyloidosis associated with atopic dermatitis: clinical resolution with cyclosporine.
Topics: Amyloidosis; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Humans; Male; Middle Aged; Treatment Outcome | 2001 |
Treatment of canine atopic dermatitis with cyclosporine: a pilot clinical study.
Topics: Administration, Oral; Animals; Chronic Disease; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Immunosuppressive Agents; Pilot Projects; Pruritus | 2001 |
Effect of low-dose cyclosporin a microemulsion on disease severity, interleukin-6, interleukin-8 and tumor necrosis factor alpha production in severe pediatric atopic dermatitis.
Topics: Adolescent; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Emulsions; Female; Humans; Immunosuppressive Agents; Infant; Interleukin-6; Interleukin-8; Male; Prospective Studies; Tumor Necrosis Factor-alpha | 2001 |
Topical tacrolimus and cyclosporin A differentially inhibit early and late effector phases of cutaneous delayed-type and immunoglobulin E hypersensitivity.
Topics: Administration, Cutaneous; Animals; Cyclosporine; Dermatitis, Allergic Contact; Dermatitis, Atopic; Female; Immunoglobulin E; Immunosuppressive Agents; Male; Mice; Mice, Inbred BALB C; Mice, Inbred CBA; Picryl Chloride; T-Lymphocytes; Tacrolimus | 2001 |
Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis.
Topics: Acute Disease; Apoptosis; Cells, Cultured; Cyclosporine; Dermatitis, Allergic Contact; Dermatitis, Atopic; Dexamethasone; fas Receptor; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interleukin-12; Keratinocytes; Sirolimus; T-Lymphocytes; Tacrolimus; Th1 Cells; Theophylline | 2001 |
Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment.
Topics: Adult; Biopsy; Cell Transformation, Neoplastic; Cyclosporine; Dermatitis, Atopic; Humans; Immunohistochemistry; Immunosuppressive Agents; Lymphoma, Large-Cell, Anaplastic; Male; Mycosis Fungoides; Polymerase Chain Reaction; Psoriasis; Skin Neoplasms; Staphylococcal Skin Infections | 2001 |
IgE autoantibodies monitored in a patient with atopic dermatitis under cyclosporin A treatment reflect tissue damage.
Topics: Adult; Autoantibodies; Cyclosporine; Dermatitis, Atopic; Humans; Immunoglobulin E; Immunosuppressive Agents; Male | 2002 |
Sequential treatment of severe atopic dermatitis with cyclosporin A and low-dose narrow-band UVB phototherapy.
Topics: Administration, Oral; Adult; Combined Modality Therapy; Cyclosporine; Dermatitis, Atopic; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Humans; Male; Prospective Studies; Severity of Illness Index; Treatment Outcome; Ultraviolet Therapy | 2002 |
Paradoxical normalization of blood pressure in a child with atopic dermatitis treated with cyclosporin.
Topics: Blood Pressure Monitoring, Ambulatory; Child; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Humans; Hypertension; Male | 2002 |
Cyclosporin ointment for psoriasis and atopic dermatitis.
Topics: Adolescent; Adult; Aged; Cyclosporine; Dermatitis, Atopic; Humans; Middle Aged; Ointments; Psoriasis | 1992 |
[Perforating keratoplasty in endogenous eczema. An indication for systemic cyclosporin A--a retrospective study of 18 patients].
Topics: Adult; Aged; Blepharitis; Cyclosporine; Dermatitis, Atopic; Female; Follow-Up Studies; Humans; Keratoconjunctivitis; Keratoconus; Keratoplasty, Penetrating; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Visual Acuity | 1992 |
Cyclosporine in atopic dermatitis. Modulation in the expression of immunologic markers in lesional skin.
Topics: Administration, Oral; Adolescent; Adult; Antigens, Differentiation; Biomarkers; Cyclosporine; Dermatitis, Atopic; Female; Humans; Immunity, Cellular; Male; Receptors, Interleukin-2; T-Lymphocytes | 1992 |
[Current therapeutic approach in atopic eczema].
Topics: Combined Modality Therapy; Cyclosporine; Dermatitis, Atopic; Eicosapentaenoic Acid; Humans; Ultraviolet Therapy | 1992 |
[Cyclosporin A in atopic dermatitis: therapeutic effect and effect on allergic reactions are dissociated from each other].
Topics: Adolescent; Adult; Animals; Antigens; Cyclosporine; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Administration Schedule; Dust; Female; Humans; Hypersensitivity, Immediate; Immunoglobulin E; Intradermal Tests; Male; Middle Aged; Mites; Patch Tests | 1991 |